(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/98351 A2

(51) International Patent Classification[7]: C07K 14/705

(21) International Application Number: PCT/US01/19275

(22) International Filing Date: 15 June 2001 (15.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/212,483	16 June 2000 (16.06.2000)	US
60/213,954	22 June 2000 (22.06.2000)	US
60/215,209	29 June 2000 (29.06.2000)	US
60/216,595	7 July 2000 (07.07.2000)	US
60/218,936	14 July 2000 (14.07.2000)	US
60/219,154	19 July 2000 (19.07.2000)	US
60/220,141	21 July 2000 (21.07.2000)	US

(71) Applicant *(for all designated States except US)*: **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LAL, Preeti** [IN/US]; P.O. Box 5142, Santa Clara, CA 95056 (US). **BAUGHN, Mariah, R.** [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). **HAFALIA, April, J., A.** [US/US]; 2227 Calle de Primavera, Santa Clara, CA 95054 (US). **NGUYEN, Danniel, B.** [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118 (US). **GANDHI, Ameena, R.** [US/US]; 837 Roble Avenue, #1, Menlo Park, CA 94025 (US). **KALLICK, Deborah, A.** [US/US]; 900 Olive Street, Menlo Park, CA 94025 (US). **GRIFFIN, Jennifer, A.** [US/US]; 33691 Mello Way, Fremont, CA 94555 (US). **YUE, Henry** [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). **KHAN, Farrah, A.** [IN/US]; 333 Escuela Avenue, #221, Mountain View, CA 94040 (US). **PATTERSON, Chandra** [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). **LU, Dyung, Aina, M.** [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). **TRIBOULEY, Catherine, M.** [FR/US]; 1121 Tennessee Street, #5, San Francisco, CA 94107 (US). **LU, Yan** [CN/US]; 3885 Corrina Way, Palo Alto, CA 94303 (US). **WALIA, Narinder, K.** [US/US]; 890 Davis Street, #205, San Leandro, CA 94577 (US). **GRAUL, Richard** [US/US]; 682-29th Avenue, San Francisco, CA 94121 (US). **YAO, Monique, G.** [US/US]; 111 Frederick Court, Mountain View, CA 94043 (US). **YANG, Junming** [CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US). **RAMKUMAR, Jayalaxmi** [IN/US]; 34359 Maybird Circle, Fremont, CA 94555 (US). **AU-YOUNG, Janice** [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). **ELLIOTT, Vicki, S.** [US/US]; 3770 Polton Place Way, San Jose, CA 95121 (US). **HERNANDEZ, Roberto** [GB/GB]; 160 Pine Tree Avenue, Canterbury Kent, CT2 7SZ (GB). **WALSH, Roderick, T.** [IE/GB]; 8 Boundary Court, St. Lawrence Road, Canterbury, Kent CT1 3EZ (GB). **BOROWSKY, Mark, L.** [US/US]; 122 Orchard Avenue, Redwood City, CA 94061 (US). **THORNTON, Michael** [US/US]; 9 Medway Road, Woodside, CA 94062-2612 (US). **HE, Ann** [CN/US]; 4601 Catalina Drive, San Jose, CA 95129 (US).

(74) Agents: **HAMLET-COX, Diana** et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/98351 A2

(54) Title: G-PROTEIN COUPLED RECEPTORS

(57) Abstract: The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

G-PROTEIN COUPLED RECEPTORS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of G-protein coupled receptors and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.

BACKGROUND OF THE INVENTION

Signal transduction is the general process by which cells respond to extracellular signals. Signal transduction across the plasma membrane begins with the binding of a signal molecule, e.g., a hormone, neurotransmitter, or growth factor, to a cell membrane receptor. The receptor, thus activated, triggers an intracellular biochemical cascade that ends with the activation of an intracellular target molecule, such as a transcription factor. This process of signal transduction regulates all types of cell functions including cell proliferation, differentiation, and gene transcription. The G-protein coupled receptors (GPCRs), encoded by one of the largest families of genes yet identified, play a central role in the transduction of extracellular signals across the plasma membrane. GPCRs have a proven history of being successful therapeutic targets.

GPCRs are integral membrane proteins characterized by the presence of seven hydrophobic transmembrane domains which together form a bundle of antiparallel alpha (α) helices. GPCRs range in size from under 400 to over 1000 amino acids (Strosberg, A.D. (1991) Eur. J. Biochem. 196:1-10; Coughlin, S.R. (1994) Curr. Opin. Cell Biol. 6:191-197). The amino-terminus of a GPCR is extracellular, is of variable length, and is often glycosylated. The carboxy-terminus is cytoplasmic and generally phosphorylated. Extracellular loops alternate with intracellular loops and link the transmembrane domains. Cysteine disulfide bridges linking the second and third extracellular loops may interact with agonists and antagonists. The most conserved domains of GPCRs are the transmembrane domains and the first two cytoplasmic loops. The transmembrane domains account, in part, for structural and functional features of the receptor. In most cases, the bundle of α helices forms a ligand-binding pocket. The extracellular N-terminal segment, or one or more of the three extracellular loops, may also participate in ligand binding. Ligand binding activates the receptor by inducing a conformational change in intracellular portions of the receptor. In turn, the large, third intracellular loop of the activated receptor interacts with a heterotrimeric guanine nucleotide binding (G) protein complex which mediates further intracellular signaling activities, including the activation of second messengers such as cyclic AMP (cAMP), phospholipase C, and inositol triphosphate, and

the interaction of the activated GPCR with ion channel proteins. (See, e.g., Watson, S. and S. Arkinstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 2-6; Bolander, F.F. (1994) Molecular Endocrinology, Academic Press, San Diego CA, pp. 162-176; Baldwin, J.M. (1994) Curr. Opin. Cell Biol. 6:180-190.)

GPCRs include receptors for sensory signal mediators (e.g., light and olfactory stimulatory molecules); adenosine, γ-aminobutyric acid (GABA), hepatocyte growth factor, melanocortins, neuropeptide Y, opioid peptides, opsins, somatostatin, tachykinins, vasoactive intestinal polypeptide family, and vasopressin; biogenic amines (e.g., dopamine, epinephrine and norepinephrine, histamine, glutamate (metabotropic effect), acetylcholine (muscarinic effect), and serotonin); chemokines; lipid mediators of inflammation (e.g., prostaglandins and prostanoids, platelet activating factor, and leukotrienes); and peptide hormones (e.g., bombesin, bradykinin, calcitonin, C5a anaphylatoxin, endothelin, follicle-stimulating hormone (FSH), gonadotropic-releasing hormone (GnRH), neurokinin, and thyrotropin-releasing hormone (TRH), and oxytocin). GPCRs which act as receptors for stimuli that have yet to be identified are known as orphan receptors.

The diversity of the GPCR family is further increased by alternative splicing. Many GPCR genes contain introns, and there are currently over 30 such receptors for which splice variants have been identified. The largest number of variations are at the protein C-terminus. N-terminal and cytoplasmic loop variants are also frequent, while variants in the extracellular loops or transmembrane domains are less common. Some receptors have more than one site at which variance can occur. The splicing variants appear to be functionally distinct, based upon observed differences in distribution, signaling, coupling, regulation, and ligand binding profiles (Kilpatrick, G.J. et al. (1999) Trends Pharmacol. Sci. 20:294-301).

GPCRs can be divided into three major subfamilies: the rhodopsin-like, secretin-like, and metabotropic glutamate receptor subfamilies. Members of these GPCR subfamilies share similar functions and the characteristic seven transmembrane structure, but have divergent amino acid sequences. The largest family consists of the rhodopsin-like GPCRs, which transmit diverse extracellular signals including hormones, neurotransmitters, and light. Rhodopsin is a photosensitive GPCR found in animal retinas. In vertebrates, rhodopsin molecules are embedded in membranous stacks found in photoreceptor (rod) cells. Each rhodopsin molecule responds to a photon of light by triggering a decrease in cGMP levels which leads to the closure of plasma membrane sodium channels. In this manner, a visual signal is converted to a neural impulse. Other rhodopsin-like GPCRs are directly involved in responding to neurotransmitters. These GPCRs include the receptors for adrenaline (adrenergic receptors), acetylcholine (muscarinic receptors), adenosine, galanin, and glutamate (N-methyl-D-aspartate/NMDA receptors). (Reviewed in Watson, S. and S. Arkinstall (1994) The G-Protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 7-9, 19-22,

32-35, 130-131, 214-216, 221-222; Habert-Ortoli, E. et al. (1994) Proc. Natl. Acad. Sci. USA 91:9780-9783.)

The galanin receptors mediate the activity of the neuroendocrine peptide galanin, which inhibits secretion of insulin, acetylcholine, serotonin and noradrenaline, and stimulates prolactin and growth hormone release. Galanin receptors are involved in feeding disorders, pain, depression, and Alzheimer's disease (Kask, K. et al. (1997) Life Sci. 60:1523-1533). Other nervous system rhodopsin-like GPCRs include a growing family of receptors for lysophosphatidic acid and other lysophospholipids, which appear to have roles in development and neuropathology (Chun, J. et al. (1999) Cell Biochem. Biophys. 30:213-242).

The largest subfamily of GPCRs, the olfactory receptors, are also members of the rhodopsin-like GPCR family. These receptors function by transducing odorant signals. Numerous distinct olfactory receptors are required to distinguish different odors. Each olfactory sensory neuron expresses only one type of olfactory receptor, and distinct spatial zones of neurons expressing distinct receptors are found in nasal passages. For example, the RA1c receptor which was isolated from a rat brain library, has been shown to be limited in expression to very distinct regions of the brain and a defined zone of the olfactory epithelium (Raming, K. et al. (1998) Receptors Channels 6:141-151). However, the expression of olfactory-like receptors is not confined to olfactory tissues. For example, three rat genes encoding olfactory-like receptors having typical GPCR characteristics showed expression patterns not only in taste and olfactory tissue, but also in male reproductive tissue (Thomas, M.B. et al. (1996) Gene 178:1-5).

Members of the secretin-like GPCR subfamily have as their ligands peptide hormones such as secretin, calcitonin, glucagon, growth hormone-releasing hormone, parathyroid hormone, and vasoactive intestinal peptide. For example, the secretin receptor responds to secretin, a peptide hormone that stimulates the secretion of enzymes and ions in the pancreas and small intestine (Watson, supra, pp. 278-283). Secretin receptors are about 450 amino acids in length and are found in the plasma membrane of gastrointestinal cells. Binding of secretin to its receptor stimulates the production of cAMP.

Examples of secretin-like GPCRs implicated in inflammation and the immune response include the EGF module-containing, mucin-like hormone receptor (Emr1) and CD97 receptor proteins. These GPCRs are members of the recently characterized EGF-TM7 receptors subfamily. These seven transmembrane hormone receptors exist as heterodimers in vivo and contain between three and seven potential calcium-binding EGF-like motifs. CD97 is predominantly expressed in leukocytes and is markedly upregulated on activated B and T cells (McKnight, A.J. and S. Gordon (1998) J. Leukoc. Biol. 63:271-280).

The third GPCR subfamily is the metabotropic glutamate receptor family. Glutamate is the

major excitatory neurotransmitter in the central nervous system. The metabotropic glutamate receptors modulate the activity of intracellular effectors, and are involved in long-term potentiation (Watson, supra, p.130). The Ca^{2+}-sensing receptor, which senses changes in the extracellular concentration of calcium ions, has a large extracellular domain including clusters of acidic amino acids which may be involved in calcium binding. The metabotropic glutamate receptor family also includes pheromone receptors, the $GABA_B$ receptors, and the taste receptors.

Other subfamilies of GPCRs include two groups of chemoreceptor genes found in the nematodes Caenorhabditis elegans and Caenorhabditis briggsae, which are distantly related to the mammalian olfactory receptor genes. The yeast pheromone receptors STE2 and STE3, involved in the response to mating factors on the cell membrane, have their own seven-transmembrane signature, as do the cAMP receptors from the slime mold Dictyostelium discoideum, which are thought to regulate the aggregation of individual cells and control the expression of numerous developmentally-regulated genes.

GPCR mutations, which may cause loss of function or constitutive activation, have been associated with numerous human diseases (Coughlin, supra). For instance, retinitis pigmentosa may arise from mutations in the rhodopsin gene. Furthermore, somatic activating mutations in the thyrotropin receptor have been reported to cause hyperfunctioning thyroid adenomas, suggesting that certain GPCRs susceptible to constitutive activation may behave as protooncogenes (Parma, J. et al. (1993) Nature 365:649-651). GPCR receptors for the following ligands also contain mutations associated with human disease: luteinizing hormone (precocious puberty); vasopressin V_2 (X-linked nephrogenic diabetes); glucagon (diabetes and hypertension); calcium (hyperparathyroidism, hypocalcuria, hypercalcemia); parathyroid hormone (short limbed dwarfism); β_3-adrenoceptor (obesity, non-insulin-dependent diabetes mellitus); growth hormone releasing hormone (dwarfism); and adrenocorticotropin (glucocorticoid deficiency) (Wilson, S. et al. (1998) Br. J. Pharmocol. 125:1387-1392; Stadel, J.M. et al. (1997) Trends Pharmacol. Sci. 18:430-437). GPCRs are also involved in depression, schizophrenia, sleeplessness, hypertension, anxiety, stress, renal failure, and several cardiovascular disorders (Horn, F. and G. Vriend (1998) J. Mol. Med. 76:464-468).

In addition, within the past 20 years several hundred new drugs have been recognized that are directed towards activating or inhibiting GPCRs. The therapeutic targets of these drugs span a wide range of diseases and disorders, including cardiovascular, gastrointestinal, and central nervous system disorders as well as cancer, osteoporosis and endometriosis (Wilson, supra; Stadel, supra). For example, the dopamine agonist L-dopa is used to treat Parkinson's disease, while a dopamine antagonist is used to treat schizophrenia and the early stages of Huntington's disease. Agonists and antagonists of adrenoceptors have been used for the treatment of asthma, high blood pressure, other cardiovascular disorders, and anxiety; muscarinic agonists are used in the treatment of glaucoma and

tachycardia; serotonin 5HT1D antagonists are used against migraine; and histamine H1 antagonists are used against allergic and anaphylactic reactions, hay fever, itching, and motion sickness (Horn, supra).

Recent research suggests potential future therapeutic uses for GPCRs in the treatment of metabolic disorders including diabetes, obesity, and osteoporosis. For example, mutant V2 vasopressin receptors causing nephrogenic diabetes could be functionally rescued in vitro by co-expression of a C-terminal V2 receptor peptide spanning the region containing the mutations. This result suggests a possible novel strategy for disease treatment (Schöneberg, T. et al. (1996) EMBO J. 15:1283-1291). Mutations in melanocortin-4 receptor (MC4R) are implicated in human weight regulation and obesity. As with the vasopressin V2 receptor mutants, these MC4R mutants are defective in trafficking to the plasma membrane (Ho, G. and R.G. MacKenzie (1999) J. Biol. Chem. 274:35816-35822), and thus might be treated with a similar strategy. The type 1 receptor for parathyroid hormone (PTH) is a GPCR that mediates the PTH-dependent regulation of calcium homeostasis in the bloodstream. Study of PTH/receptor interactions may enable the development of novel PTH receptor ligands for the treatment of osteoporosis (Mannstadt, M. et al. (1999) Am. J. Physiol. 277:F665-F675).

The chemokine receptor group of GPCRs have potential therapeutic utility in inflammation and infectious disease. (For review, see Locati, M. and P.M. Murphy (1999) Annu. Rev. Med. 50:425-440.) Chemokines are small polypeptides that act as intracellular signals in the regulation of leukocyte trafficking, hematopoiesis, and angiogenesis. Targeted disruption of various chemokine receptors in mice indicates that these receptors play roles in pathologic inflammation and in autoimmune disorders such as multiple sclerosis. Chemokine receptors are also exploited by infectious agents, including herpesviruses and the human immunodeficiency virus (HIV-1) to facilitate infection. A truncated version of chemokine receptor CCR5, which acts as a coreceptor for infection of T-cells by HIV-1, results in resistance to AIDS, suggesting that CCR5 antagonists could be useful in preventing the development of AIDS.

The discovery of new G-protein coupled receptors and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, G-protein coupled receptors, referred to

collectively as "GCREC" and individually as "GCREC-1," "GCREC-2," "GCREC-3," "GCREC-4," "GCREC-5," "GCREC-6," "GCREC-7," "GCREC-8," "GCREC-9," "GCREC-10," "GCREC-11," "GCREC-12," "GCREC-13," "GCREC-14," "GCREC-15," "GCREC-16," and "GCREC-17." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-17.

The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-17. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:18-34.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, c) a

biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17.

The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:18-34, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:18-34, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:18-34, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:18-34, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:18-34, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:18-34, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-17. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test

compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:18-34, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:18-34, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:18-34, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:18-34, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:18-34, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.

Table 3 shows structural features of polypeptide sequences of the invention, including

predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

Table 8 shows tissue-specific expression of polynucleotides of the invention.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"GCREC" refers to the amino acid sequences of substantially purified GCREC obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and

human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of GCREC. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by directly interacting with GCREC or by acting on components of the biological pathway in which GCREC participates.

An "allelic variant" is an alternative form of the gene encoding GCREC. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding GCREC include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as GCREC or a polypeptide with at least one functional characteristic of GCREC. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding GCREC, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GCREC. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GCREC. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of GCREC is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well

known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of GCREC. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by directly interacting with GCREC or by acting on components of the biological pathway in which GCREC participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, $F(ab')_2$, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind GCREC polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic GCREC, or of any oligopeptide

thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding GCREC or fragments of GCREC may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

Original Residue	Conservative Substitution
Ala	Gly, Ser
Arg	His, Lys
Asn	Asp, Gln, His
Asp	Asn, Glu
Cys	Ala, Ser
Gln	Asn, Glu, His
Glu	Asp, Gln, His
Gly	Ala
His	Asn, Arg, Gln, Glu
Ile	Leu, Val
Leu	Ile, Val
Lys	Arg, Gln, Glu
Met	Leu, Ile

Phe	His, Met, Leu, Trp, Tyr
Ser	Cys, Thr
Thr	Ser, Val
Trp	Phe, Tyr
Tyr	His, Phe, Trp
Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

"Differential expression" refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

A "fragment" is a unique portion of GCREC or the polynucleotide encoding GCREC which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:18-34 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:18-34, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:18-34 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:18-34 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:18-34 and the region of SEQ ID NO:18-34 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-17 is encoded by a fragment of SEQ ID NO:18-34. A fragment of SEQ ID NO:1-17 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-17. For example, a fragment of SEQ ID NO:1-17 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-17. The precise length of a fragment of SEQ ID NO:1-17 and the region of SEQ ID NO:1-17 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment

Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2.html. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the

site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized

after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of GCREC which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of GCREC which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of GCREC. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of GCREC.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an GCREC may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of GCREC.

"Probe" refers to nucleic acid sequences encoding GCREC, their complements, or fragments

thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping

Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing GCREC, nucleic acids encoding GCREC, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or

cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in

vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

The invention is based on the discovery of new human G-protein coupled receptors

(GCREC), the polynucleotides encoding GCREC, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections.

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are G-protein coupled receptors. For example, SEQ ID NO:1 is 99% identical to human orphan G protein-coupled receptor; GPC-R (GenBank ID g2865470) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 1.5e-217, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:1 also contains an orphan G protein-coupled receptor domain as determined by searching for statistically significant matches in the DOMO database using a Blocks IMProved Searcher (BLIMPS) that searches for gene families, sequence

homology, and structural fingerprint regions. (See Table 3.) SEQ ID NO:1 additionally contains a G-protein coupled receptor subclass 7 transmembrane receptor (rhodopsin family) domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS-PRINTS, BLIMPS-BLOCKS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:1 is a G-protein coupled receptor. In an alternative example, SEQ ID NO:8 is 79% identical to rat serotonin receptor (GenBank ID g310075) as determined by BLAST. (See Table 2.) The BLAST probability score is 2.0e-151. SEQ ID NO:8 also contains G-protein coupled receptor domain structure as determined by searching for statistically significant matches in the HMM-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and PROFILESCAN analyses, as well as BLAST comparisons to protein signature sequences in the PRODOM and DOMO databases, provide further corroborative evidence that SEQ ID NO:8 is a G-protein coupled receptor. In an alternative example, SEQ ID NO:10 is 92% identical to the human leukocyte platelet-activating factor receptor, a G-protein coupled receptor (GenBank ID g189270), as determined by BLAST. (See Table 2.) The BLAST probability score is 2.9e-147. SEQ ID NO:10 also contains 7-transmembrane receptor domains, characteristic of G-protein coupled receptors, as well as a receptor binding domain, as determined by searching for statistically significant matches in the HMM-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and MOTIFS analyses provide further corroborative evidence that SEQ ID NO:10 is a G-protein coupled receptor. In an alternative example, SEQ ID NO:11 is 99% identical to human endothelin receptor B delta 3 (GenBank ID g4580924), as determined by BLAST. (See Table 2.) The BLAST probability score is 2.3e-289. SEQ ID NO:11 also contains 7-transmembrane receptor domains as determined by searching for statictically significant matches in the HMM-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:11 is an endothelin receptor. In an alternative example, SEQ ID NO:16 is 50% identical to the rat taste bud receptor protein TB641 (GenBank ID g1256393), as determined by BLAST. (See Table 2.) The BLAST probability score is 2.0e-59. BLAST searches of the PRODOM and DOMO databases also indicate that SEQ ID NO:16 has homology with receptor protein and G-protein coupled receptor domains. SEQ ID NO:16 also contains a rhodopsin family 7-transmembrane receptor domain, as determined by searching for statistically significant matches in the HMM-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:16 is a G-protein coupled receptor. In an alternative example, SEQ ID NO:17 is 41% identical to the rat G-protein coupled receptor OL1 (GenBank ID g1016362), as determined by BLAST. (See Table 2.) The BLAST probability score is

3.6e-69. SEQ ID NO:17 also contains a 7-transmembrane receptor (rhodopsin family) domain as determined by searching for statistically significant matches in the HMM-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:17 is a G-protein coupled receptor of the rhodopsin family. SEQ ID NO:2-7, SEQ ID NO:9, and SEQ ID NO:12-15 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-17 are described in Table 7.

As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention. Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:18-34 or that distinguish between SEQ ID NO:18-34 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5′) and stop (3′) positions of the cDNA and/or genomic sequences in column 5 relative to their respective full length sequences.

The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 2432516H1 is the identification number of an Incyte cDNA sequence, and BRAVUNT02 is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., 71687857V1). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs which contributed to the assembly of the full length polynucleotide sequences. Alternatively, the identification numbers in column 5 may refer to coding regions predicted by Genscan analysis of genomic DNA. For example, GNN.g6479070.edit is the identification number of a Genscan-predicted coding sequence, with g6479070 being the GenBank identification number of the sequence to which Genscan was applied. The Genscan-predicted coding sequences may have been edited prior to assembly. (See Example IV.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, FL210313_00001 represents a "stitched" sequence in which 210313 is the identification number of the cluster of sequences to

which the algorithm was applied, and 00001 is the number of the prediction generated by the algorithm. (See Example V.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon-stretching" algorithm. For example, FL7655614_g7406476_g156725 is the identification number of a "stretched" sequence, with 7655614 being the Incyte project identification number, g7406476 being the GenBank identification number of the human genomic sequence to which the "exon-stretching" algorithm was applied, and g156725 being the GenBank identification number of the nearest GenBank protein homolog. (See Example V.) In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

Table 8 shows tissue-specific expression of polynucleotides of the invention. Column 1 lists groups of tissues which were tested by polymerase chain reaction (PCR) for expression of the polynucleotides. The remaining columns indicate whether a particular polynucleotide was expressed in each tissue group. Detection of a PCR product indicated positive expression, denoted by a "+" sign, while inability to detect a PCR product indicated a lack of expression, denoted by a "-" sign.

The invention also encompasses GCREC variants. A preferred GCREC variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the GCREC amino acid sequence, and which contains at least one functional or structural characteristic of GCREC.

The invention also encompasses polynucleotides which encode GCREC. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:18-34, which encodes GCREC. The polynucleotide sequences of SEQ ID NO:18-34, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding GCREC. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding GCREC. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID

NO:18-34 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:18-34. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of GCREC.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding GCREC, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring GCREC, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode GCREC and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring GCREC under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GCREC or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GCREC and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode GCREC and GCREC derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GCREC or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:18-34 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment

of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding GCREC may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include

sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode GCREC may be cloned in recombinant DNA molecules that direct expression of GCREC, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express GCREC.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter GCREC-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of GCREC, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random

point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding GCREC may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, GCREC itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of GCREC, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active GCREC, the nucleotide sequences encoding GCREC or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding GCREC. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GCREC. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding GCREC and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used.

(See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GCREC and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding GCREC. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding GCREC. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding GCREC can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding GCREC into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol.

Chem. 264:5503-5509.) When large quantities of GCREC are needed, e.g. for the production of antibodies, vectors which direct high level expression of GCREC may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of GCREC. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of GCREC. Transcription of sequences encoding GCREC may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GCREC may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses GCREC in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of GCREC in cell lines is preferred. For example, sequences encoding GCREC can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or

endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk*⁻ and *apr*⁻ cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), ß glucuronidase and its substrate ß-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding GCREC is inserted within a marker gene sequence, transformed cells containing sequences encoding GCREC can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GCREC under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding GCREC and that express GCREC may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of GCREC using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques

include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GCREC is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GCREC include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding GCREC, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding GCREC may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GCREC may be designed to contain signal sequences which direct secretion of GCREC through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GCREC may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric GCREC protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of GCREC activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the GCREC encoding sequence and the heterologous protein sequence, so that GCREC may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled GCREC may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ^{35}S-methionine.

GCREC of the present invention or fragments thereof may be used to screen for compounds that specifically bind to GCREC. At least one and up to a plurality of test compounds may be screened for specific binding to GCREC. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of GCREC, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which GCREC binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express GCREC, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or

E. coli. Cells expressing GCREC or cell membrane fractions which contain GCREC are then contacted with a test compound and binding, stimulation, or inhibition of activity of either GCREC or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with GCREC, either in solution or affixed to a solid support, and detecting the binding of GCREC to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

GCREC of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of GCREC. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for GCREC activity, wherein GCREC is combined with at least one test compound, and the activity of GCREC in the presence of a test compound is compared with the activity of GCREC in the absence of the test compound. A change in the activity of GCREC in the presence of the test compound is indicative of a compound that modulates the activity of GCREC. Alternatively, a test compound is combined with an in vitro or cell-free system comprising GCREC under conditions suitable for GCREC activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of GCREC may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding GCREC or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred

to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding GCREC may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding GCREC can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding GCREC is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress GCREC, e.g., by secreting GCREC in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of GCREC and G-protein coupled receptors. In addition, the expression of GCREC is closely associated with breast tissue, megakaryoblast cells, prostate tumor, dorsal root ganglion tissue, and pituitary gland tissue. Therefore, GCREC appears to play a role in cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections. In the treatment of disorders associated with increased GCREC expression or activity, it is desirable to decrease the expression or activity of GCREC. In the treatment of disorders associated with decreased GCREC expression or activity, it is desirable to increase the expression or activity of GCREC.

Therefore, in one embodiment, GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia,

gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the

liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha$_1$-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and tongavirus.

In another embodiment, a vector capable of expressing GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified GCREC in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of GCREC may be

administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those listed above.

In a further embodiment, an antagonist of GCREC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCREC. Examples of such disorders include, but are not limited to, those cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, described above. In one aspect, an antibody which specifically binds GCREC may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express GCREC.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding GCREC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCREC including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of GCREC may be produced using methods which are generally known in the art. In particular, purified GCREC may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GCREC. Antibodies to GCREC may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with GCREC or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to GCREC have an amino acid sequence consisting of at least about 5 amino acids, and generally will

consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of GCREC amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to GCREC may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce GCREC-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for GCREC may also be generated. For example, such fragments include, but are not limited to, $F(ab')_2$ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GCREC and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering GCREC epitopes is generally used, but a competitive binding assay

may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for GCREC. Affinity is expressed as an association constant, K_a, which is defined as the molar concentration of GCREC-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple GCREC epitopes, represents the average affinity, or avidity, of the antibodies for GCREC. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular GCREC epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the GCREC-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of GCREC, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of GCREC-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding GCREC, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding GCREC. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding GCREC. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g.,

Slater, J.E. et al. (1998) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) Blood 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R.J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M.C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding GCREC may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in GCREC expression or regulation causes disease, the expression of GCREC from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in GCREC are treated by constructing mammalian expression vectors encoding GCREC and introducing these vectors by mechanical means into GCREC-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H. Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of GCREC include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). GCREC may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding GCREC from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to GCREC expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding GCREC under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by

reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., $CD4^+$ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding GCREC to cells which have one or more genetic abnormalities with respect to the expression of GCREC. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding GCREC to target cells which have one or more genetic abnormalities with respect to the expression of GCREC. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing GCREC to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding GCREC to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for GCREC into the alphavirus genome in place of the capsid-coding region results in the production of a large number of GCREC-coding RNAs and the synthesis of high levels of GCREC in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of GCREC into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GCREC.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA,

GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding GCREC. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding GCREC. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased GCREC expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding GCREC may be therapeutically useful, and in the treatment of disorders associated with decreased GCREC expression or activity, a compound which specifically promotes expression of the polynucleotide encoding GCREC may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method

commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding GCREC is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding GCREC are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding GCREC. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins.

Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of GCREC, antibodies to GCREC, and mimetics, agonists, antagonists, or inhibitors of GCREC.

The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising GCREC or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, GCREC or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example GCREC or fragments thereof, antibodies of GCREC, and agonists, antagonists or inhibitors of GCREC, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such

as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind GCREC may be used for the diagnosis of disorders characterized by expression of GCREC, or in assays to monitor patients being treated with GCREC or agonists, antagonists, or inhibitors of GCREC. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for GCREC include methods which utilize the antibody and a label to detect GCREC in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring GCREC, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of GCREC expression. Normal or standard values for GCREC expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to

GCREC under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of GCREC expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding GCREC may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of GCREC may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of GCREC, and to monitor regulation of GCREC levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding GCREC or closely related molecules may be used to identify nucleic acid sequences which encode GCREC. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding GCREC, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the GCREC encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:18-34 or from genomic sequences including promoters, enhancers, and introns of the GCREC gene.

Means for producing specific hybridization probes for DNAs encoding GCREC include the cloning of polynucleotide sequences encoding GCREC or GCREC derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding GCREC may be used for the diagnosis of disorders associated with expression of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in

particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis,

pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha$_1$-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and tongavirus. The polynucleotide sequences encoding GCREC may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered GCREC expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding GCREC may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding GCREC may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a

suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding GCREC in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of GCREC, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding GCREC, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding GCREC may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding GCREC, or a fragment of a polynucleotide complementary to the polynucleotide encoding GCREC, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC may be used to detect single nucleotide polymorphisms (SNPs). SNPs are

substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of GCREC include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, GCREC, fragments of GCREC, or antibodies specific for GCREC may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of

Environmental Health Sciences, released February 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for GCREC to quantify the levels of GCREC expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem.

270:103-111; Mendoze, L.G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding GCREC may be

used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding GCREC on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, GCREC, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes

between GCREC and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with GCREC, or fragments thereof, and washed. Bound GCREC is then detected by methods well known in the art. Purified GCREC can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GCREC specifically compete with a test compound for binding GCREC. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GCREC.

In additional embodiments, the nucleotide sequences which encode GCREC may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, including U.S. Ser. No. 60/212,483, U.S. Ser. No. 60/213,954, U.S. Ser. No. 60/215,209, U.S. Ser. No. 60/216,595, U.S. Ser. No. 60/218,936, U.S. Ser. No. 60/219,154, and U.S. Ser. No. 60/220,141, are expressly incorporated by reference herein.

EXAMPLES

I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length

polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:18-34. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.

IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative G-protein coupled receptors were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode G-protein coupled receptors, the encoded polypeptides were analyzed by querying against PFAM models for G-protein coupled receptors. Potential G-protein coupled receptors were also identified by homology to Incyte cDNA sequences that had been annotated as G-protein coupled receptors. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available,

this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data

"Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

"Stretched" Sequences

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The

GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of GCREC Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:18-34 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:18-34 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score x Percent Identity}}{\text{5 x minimum \{length(Seq. 1), length(Seq. 2)\}}}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding GCREC are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding GCREC. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

VIII. Extension of GCREC Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was

synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+}, $(NH_4)_2SO_4$, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 µl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 µl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:18-34 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μCi of [γ-^{32}P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra.), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999),

supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)$^+$ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)$^+$ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/µl oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/µl RNase inhibitor, 500 µM dATP, 500 µM dGTP, 500 µM dTTP, 40 µM dCTP, 40 µM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)$^+$ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)$^+$ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37° C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 µl 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 μl of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60° C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μl of sample mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65° C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm^2 coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45° C in a second wash buffer (0.1X SSC), and dried.

Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines

at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XI. Complementary Polynucleotides

Sequences complementary to the GCREC-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring GCREC. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same

procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of GCREC. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GCREC-encoding transcript.

XII. Expression of GCREC

Expression and purification of GCREC is achieved using bacterial or virus-based expression systems. For expression of GCREC in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express GCREC upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of GCREC in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding GCREC by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, GCREC is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from GCREC at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified GCREC obtained by these methods can be used directly in the assays

shown in Examples XVI, XVII, and XVIII, where applicable.

XIII. Functional Assays

GCREC function is assessed by expressing the sequences encoding GCREC at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of GCREC on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding GCREC and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding GCREC and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIV. Production of GCREC Specific Antibodies

GCREC substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the GCREC amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-GCREC activity by, for example, binding the peptide or GCREC to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XV. Purification of Naturally Occurring GCREC Using Specific Antibodies

Naturally occurring or recombinant GCREC is substantially purified by immunoaffinity chromatography using antibodies specific for GCREC. An immunoaffinity column is constructed by covalently coupling anti-GCREC antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing GCREC are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of GCREC (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GCREC binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GCREC is collected.

XVI. Identification of Molecules Which Interact with GCREC

Molecules which interact with GCREC may include agonists and antagonists, as well as molecules involved in signal transduction, such as G proteins. GCREC, or a fragment thereof, is labeled with ^{125}I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) A fragment of GCREC includes, for example, a fragment comprising one or more of the three extracellular loops, the extracellular N-terminal region, or the third intracellular loop. Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GCREC, washed, and any wells with labeled GCREC complex are assayed. Data obtained using different concentrations of GCREC are used to calculate values for the number, affinity, and association of GCREC with the candidate ligand molecules.

Alternatively, molecules interacting with GCREC are analyzed using the yeast two-hybrid

system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech). GCREC may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

Potential GCREC agonists or antagonists may be tested for activation or inhibition of GCREC receptor activity using the assays described in sections XVII and XVIII. Candidate molecules may be selected from known GPCR agonists or antagonists, peptide libraries, or combinatorial chemical libraries.

Methods for detecting interactions of GCREC with intracellular signal transduction molecules such as G proteins are based on the premise that internal segments or cytoplasmic domains from an orphan G protein-coupled seven transmembrane receptor may be exchanged with the analogous domains of a known G protein-coupled seven transmembrane receptor and used to identify the G-proteins and downstream signaling pathways activated by the orphan receptor domains (Kobilka, B.K. et al. (1988) Science 240:1310-1316). In an analogous fashion, domains of the orphan receptor may be cloned as a portion of a fusion protein and used in binding assays to demonstrate interactions with specific G proteins. Studies have shown that the third intracellular loop of G protein-coupled seven transmembrane receptors is important for G protein interaction and signal transduction (Conklin, B.R. et al. (1993) Cell 73:631-641). For example, the DNA fragment corresponding to the third intracellular loop of GCREC may be amplified by the polymerase chain reaction (PCR) and subcloned into a fusion vector such as pGEX (Pharmacia Biotech). The construct is transformed into an appropriate bacterial host, induced, and the fusion protein is purified from the cell lysate by glutathione-Sepharose 4B (Pharmacia Biotech) affinity chromatography.

For in vitro binding assays, cell extracts containing G proteins are prepared by extraction with 50 mM Tris, pH 7.8, 1 mM EGTA, 5 mM $MgCl_2$, 20 mM CHAPS, 20% glycerol, 10 µg of both aprotinin and leupeptin, and 20 µl of 50 mM phenylmethylsulfonyl fluoride. The lysate is incubated on ice for 45 min with constant stirring, centrifuged at 23,000 g for 15 min at 4°C, and the supernatant is collected. 750 µg of cell extract is incubated with glutathione S-transferase (GST) fusion protein beads for 2 h at 4°C. The GST beads are washed five times with phosphate-buffered saline. Bound G subunits are detected by [^{32}P]ADP-ribosylation with pertussis or cholera toxins. The reactions are terminated by the addition of SDS sample buffer (4.6% (w/v) SDS, 10% (v/v) β-mercaptoethanol, 20% (w/v) glycerol, 95.2 mM Tris-HCl, pH 6.8, 0.01% (w/v) bromphenol blue). The [^{32}P]ADP-labeled proteins are separated on 10% SDS-PAGE gels, and autoradiographed. The separated proteins in these gels are transferred to nitrocellulose paper, blocked with blotto (5% nonfat

dried milk, 50 mM Tris-HCl (pH 8.0), 2 mM $CaCl_2$, 80 mM NaCl, 0.02% NaN_3, and 0.2% Nonidet P-40) for 1 hour at room temperature, followed by incubation for 1.5 hours with Gα subtype selective antibodies (1:500; Calbiochem-Novabiochem). After three washes, blots are incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin (1:2000, Cappel, Westchester PA) and visualized by the chemiluminescence-based ECL method (Amersham Corp.).

XVII. Demonstration of GCREC Activity

An assay for GCREC activity measures the expression of GCREC on the cell surface. cDNA encoding GCREC is transfected into an appropriate mammalian cell line. Cell surface proteins are labeled with biotin as described (de la Fuente, M.A. et al. (1997) Blood 90:2398-2405). Immunoprecipitations are performed using GCREC-specific antibodies, and immunoprecipitated samples are analyzed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of GCREC expressed on the cell surface.

In the alternative, an assay for GCREC activity is based on a prototypical assay for ligand/receptor-mediated modulation of cell proliferation. This assay measures the rate of DNA synthesis in Swiss mouse 3T3 cells. A plasmid containing polynucleotides encoding GCREC is added to quiescent 3T3 cultured cells using transfection methods well known in the art. The transiently transfected cells are then incubated in the presence of [^{3}H]thymidine, a radioactive DNA precursor molecule. Varying amounts of GCREC ligand are then added to the cultured cells. Incorporation of [^{3}H]thymidine into acid-precipitable DNA is measured over an appropriate time interval using a radioisotope counter, and the amount incorporated is directly proportional to the amount of newly synthesized DNA. A linear dose-response curve over at least a hundred-fold GCREC ligand concentration range is indicative of receptor activity. One unit of activity per milliliter is defined as the concentration of GCREC producing a 50% response level, where 100% represents maximal incorporation of [^{3}H]thymidine into acid-precipitable DNA (McKay, I. and I. Leigh, eds. (1993) Growth Factors: A Practical Approach, Oxford University Press, New York NY, p. 73.)

In a further alternative, the assay for GCREC activity is based upon the ability of GPCR family proteins to modulate G protein-activated second messenger signal transduction pathways (e.g., cAMP; Gaudin, P. et al. (1998) J. Biol. Chem. 273:4990-4996). A plasmid encoding full length GCREC is transfected into a mammalian cell line (e.g., Chinese hamster ovary (CHO) or human embryonic kidney (HEK-293) cell lines) using methods well-known in the art. Transfected cells are grown in 12-well trays in culture medium for 48 hours, then the culture medium is discarded, and the attached cells are gently washed with PBS. The cells are then incubated in culture medium with or without ligand for 30 minutes, then the medium is removed and cells lysed by treatment with 1 M

perchloric acid. The cAMP levels in the lysate are measured by radioimmunoassay using methods well-known in the art. Changes in the levels of cAMP in the lysate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC present in the transfected cells.

To measure changes in inositol phosphate levels, the cells are grown in 24-well plates containing $1x10^5$ cells/well and incubated with inositol-free media and [^{3}H]myoinositol, 2 μCi/well, for 48 hr. The culture medium is removed, and the cells washed with buffer containing 10 mM LiCl followed by addition of ligand. The reaction is stopped by addition of perchloric acid. Inositol phosphates are extracted and separated on Dowex AG1-X8 (Bio-Rad) anion exchange resin, and the total labeled inositol phosphates counted by liquid scintillation. Changes in the levels of labeled inositol phosphate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC present in the transfected cells.

XVIII. Identification of GCREC Ligands

GCREC is expressed in a eukaryotic cell line such as CHO (Chinese Hamster Ovary) or HEK (Human Embryonic Kidney) 293 which have a good history of GPCR expression and which contain a wide range of G-proteins allowing for functional coupling of the expressed GCREC to downstream effectors. The transformed cells are assayed for activation of the expressed receptors in the presence of candidate ligands. Activity is measured by changes in intracellular second messengers, such as cyclic AMP or Ca^{2+}. These may be measured directly using standard methods well known in the art, or by the use of reporter gene assays in which a luminescent protein (e.g. firefly luciferase or green fluorescent protein) is under the transcriptional control of a promoter responsive to the stimulation of protein kinase C by the activated receptor (Milligan, G. et al. (1996) Trends Pharmacol. Sci. 17:235-237). Assay technologies are available for both of these second messenger systems to allow high throughput readout in multi-well plate format, such as the adenylyl cyclase activation FlashPlate Assay (NEN Life Sciences Products), or fluorescent Ca^{2+} indicators such as Fluo-4 AM (Molecular Probes) in combination with the FLIPR fluorimetric plate reading system (Molecular Devices). In cases where the physiologically relevant second messenger pathway is not known, GCREC may be coexpressed with the G-proteins $G_{\alpha 15/16}$ which have been demonstrated to couple to a wide range of G-proteins (Offermanns, S. and M.I. Simon (1995) J. Biol. Chem. 270:15175-15180), in order to funnel the signal transduction of the GCREC through a pathway involving phospholipase C and Ca^{2+} mobilization. Alternatively, GCREC may be expressed in engineered yeast systems which lack endogenous GPCRs, thus providing the advantage of a null background for GCREC activation screening. These yeast systems substitute a human GPCR and G_α protein for the corresponding components of the endogenous yeast pheromone receptor pathway. Downstream signaling pathways are also modified so that the normal yeast response to the signal is converted to positive growth on

selective media or to reporter gene expression (Broach, J.R. and J. Thorner (1996) Nature 384 (supp.):14-16). The receptors are screened against putative ligands including known GPCR ligands and other naturally occurring bioactive molecules. Biological extracts from tissues, biological fluids and cell supernatants are also screened.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
1714538	1	1714538CD1	18	1714538CB1
3406743	2	3406743CD1	19	3406743CB1
3485895	3	3485895CD1	20	3485895CB1
7476102	4	7476102CD1	21	7476102CB1
2432942	5	2432942CD1	22	2432942CB1
4630911	6	4630911CD1	23	4630911CB1
7472432	7	7472432CD1	24	7472432CB1
7474977	8	7474977CD1	25	7474977CB1
7474848	9	7474848CD1	26	7474848CB1
7655614	10	7655614CD1	27	7655614CB1
6792419	11	6792419CD1	28	6792419CB1
7474790	12	7474790CD1	29	7474790CB1
7474816	13	7474816CD1	30	7474816CB1
7476172	14	7476172CD1	31	7476172CB1
7472141	15	7472141CD1	32	7472141CB1
7472137	16	7472137CD1	33	7472137CB1
7477934	17	7477934CD1	34	7477934CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability Score	GenBank Homolog
1	1714538CD1	g2865470	1.50E-217	[Homo sapiens] orphan G protein-coupled receptor; GPC-R (Tan, C. et al. (1998) Genomics 52:223-229)
		g10946201	0	[Homo sapiens] neuromedin U receptor 1
2	3406743CD1	g1902966	3.40E-16	[Mus sp.] oxytocin receptor (Kubota, Y. et al. (1996) Mol. Cell Endocrinol. 124:25-32)
3	3485895CD1	g13517983	0	[Homo sapiens] G-protein coupled receptor 91
		g767873	1.10E-47	[Rattus norvegicus] P2Y purinoceptor (Tokuyama, Y. et al. (1995) Biochem. Biophys. Res. Commun. 211:211-218)
4	7476102CD1	g202543	1.50E-12	[Rattus norvegicus] serotonin receptor
5	2432942CD1	g6006811	6.80E-73	[Mus musculus] serpentine receptor
6	4630911CD1	g13517962	0	[Homo sapiens] putative purinergic receptor
		g2231669	5.00E-45	[Homo sapiens] purinergic receptor P2Y9
7	7472432CD1	g2736345	4.00E-27	[Caenorhabditis elegans] contains similarity to G-coupled protein
8	7474977CD1	g310075	2.00E-151	[Rattus norvegicus] serotonin receptor
9	7474848CD1	g5019562	1.10E-37	[Homo sapiens] MAS-related G protein-coupled receptor
		g205314	9.70E-44	[Rattus norvegicus] mas oncogene (GPCR) encoded protein (Young, D. et al. (1988) Proc. Natl. Acad. Sci. USA 85:5339-5342)
10	7655614CD1	g189270	2.90E-147	[Homo sapiens] leukocyte platelet-activating factor receptor (GPCR) (Kunz, D. et al. (1992) J. Biol. Chem. 267:9101-9106)
11	6792419CD1	g4580924	2.30E-289	[Homo sapiens] endothelin receptor B delta 3 (Tsutsumi, M. et al. (1999) Gene 228:43-49)
12	7474790CD1	g2198745	2.10E-30	[Oryctolagus cuniculus] alpha 1a-adrenoceptor

Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability Score	GenBank Homolog
13	7474816CD1	g11967419	4.00E-41	[Mus musculus] vomeronasal receptor V1RC3
		g1055254	2.70E-25	[Rattus norvegicus] pheromone receptor VN6 (Dulac, C. and R. Axel (1995) Cell 83:195-206)
14	7476172CD1	g5809686	2.60E-163	[Carassius auratus] odorant receptor 5.24
		g3130153	2.80E-117	[Takifugu rubripes] calcium2+ sensing receptor (Naito, T. et al. (1998) Proc. Natl. Acad. Sci. USA 95:5178-5181)
15	7472141CD1	g7340541	1.90E-148	[Mus musculus] bM332P19.1 (novel 7 transmembrane receptor protein, rhodopsin family, olfactory receptor like) (mm17M1-12)
16	7472137CD1	g1256393	2.00E-59	[Rattus norvegicus] taste bud receptor protein TB 641 (Thomas, M.B. et al. (1996) Gene 178:1-5)
		g11692583	1.00E-116	[Mus musculus] odorant receptor M34
17	7477934CD1	g12007423	2.00E-77	[Mus musculus] T2 olfactory receptor
		g1016362	3.60E-69	[Rattus norvegicus] OL1 receptor (Drutel, G. (1995) Receptors Channels 3:33-40)

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	1714538CD1	426	T366 T397 T282 S360	N7 N27 N41 N151 N196	Rhodopsin-like GPCR superfamily PR00237: P62-L86, T95-L116, F141-V163, H177-S198, V232-G255, V295-M319, H338-R364	BLIMPS-PRINTS
					ORPHAN G PROTEIN-COUPLED RECEPTOR PD027492: M24-K89	BLAST-PRODOM
					ORPHAN G PROTEIN-COUPLED RECEPTOR PD061371: S357-S426	BLAST-PRODOM
					RECEPTOR COUPLED G-PROTEIN TRANSMEMBRANE GLYCOPROTEIN PHOSPHORYLATION LIPOPROTEIN PALMITATE FAMILY PD000009: R87-P195	BLAST-PRODOM
					G-PROTEIN COUPLED RECEPTORS DM00013: I63-L371, Y67-R259, Y67-L258, L59-R272	BLAST-DOMO
					G Protein Receptor: A147-V163	MOTIFS
					Transmembrane domain: M61-C82, A236-V254	HMMER
					7 transmembrane receptor (rhodopsin family) 7tm_1: G77-Y356	HMMER-PFAM
					G-protein coupled receptor BL00237: F127-P166, F240-C251, R290-D316, G348-R364	BLIMPS-BLOCKS
					G-protein coupled receptors signature: L139-V185	PROFILESCAN
2	3406743CD1	259	S41 S131 S156 S242	N15 N27 N60	G-PROTEIN COUPLED RECEPTORS DM00013|P30559|32-344:R43-W176	BLAST-DOMO
					Signal cleavage: M1-A58	SPSCAN
					Transmembrane domain: R45-C65	HMMER
					Rhodopsin-like GPCR super family PR00237: V44-C68, M82-S103, Q129-P151, A182-L205	BLIMPS-PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
3	3485895CD1	379	S111 T216 S222 S375 T55 S96 S142 S307	N53 N101 N104 N109 N213	G-protein coupled receptor BL00237D: N332-R348	BLIMPS-BLOCKS
					G-protein coupled receptors signature : Y145-I191	PROFILESCAN
					Rhodopsin-like GPCR super family PR00237: Y70-I94, S103-L124, L147-I169, 183-P204, S233-A256, P275-V299, Y322-R348	BLIMPS-PRINTS
					RECEPTOR COUPLED G-PROTEIN TRANSMEMBRANE GLYCOPROTEIN PHOSPHORYLATION LIPOPROTEIN PALMITATE PD000009: S103-I206	BLAST-PRODOM
					G Protein Receptor: T153-I169	MOTIFS
					G-PROTEIN COUPLED RECEPTORS DM00013: Y69-R356, K68-G344, L71-L351	BLAST-DOMO
					Transmembrane domain: I187-I206, M234-Y253, L276-M296, N319-L342	HMMER
					7 transmembrane receptor (rhodopsin family) 7tm_1: G85-Y340	HMMER-PFAM
					G-protein coupled receptor BL00237: W133-P172, F241-Y252, L270-M296	BLIMPS-BLOCKS
4	7476102CD1	396	S337 Y86	N34	Leucine Zipper: L80-L101	MOTIFS
					Rhodopsin-like GPCR superfamily PR00237: V128-V150, A164-W185, T220-Y243	BLIMPS-PRINTS
					G-PROTEIN COUPLED RECEPTORS DM00013: S46-G333, L54-E196	BLAST-DOMO
					Signal cleavage: M1-A65	SPSCAN
					Transmembrane domain: L87-I106, P211-C231	HMMER
					Rhodopsin-like GPCR super family PR00237B: H85-I106	BLIMPS-PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
5	2432942CD1	528	S277 S29 S375 S449 S45 S505 S510 T23 T437 T93	N146 N147 N173 N179 N18 N394 N400 N58 N65	G-protein coupled receptor: PD000752: E243-K515	BLAST-PRODOM
					G-protein coupled receptor BL00649: A: G395-L422; B: G255-L300; C: C314-L339; D: G362-I386; G: S493-I518	BLIMPS-BLOCKS
					Secretin-like GPCR superfamily PR00249: A: Y250-R274; B: R282-M306; C: A316-L339; D: V355-V380; F: D455-F475; G: L485-Q506	BLIMPS-PRINTS
					signal peptide: M1-T21	HMMER
					transmembrane domain: I251-R274, W470-F497	HMMER
					7 transmembrane receptor (Secretin family) 7tm_2: L245-A512	HMMER-PFAM
					Latrophilin/CL-1-like GPS domain: GPS: Y185-A238,	HMMER-PFAM
6	4630911CD1	361	S141 S239 S313 S323 S332 T185 T215 T233 T41 T79	N192 N350 N39	PUTATIVE PURINERGIC RECEPTOR P2Y10: PD055638:S16-V83	BLAST-PRODOM
					G-protein coupled receptor BL00237: A: W112-P151; B: F222-T233; C: G251-S277; D: N312-R328	BLIMPS-BLOCKS
					Rhodopsin-like GPCR superfamily PR00237: A: I49-Y73; B: A82-R103; C: K126-L148; D: Y161-L182; E: M214-V237; F: A256-L280; G: H302-R328	BLIMPS-PRINTS
					transmembrane domain: A51-Y73, A82-Y106, I134-F152, I165-L183, V211-T233	HMMER
					7 transmembrane receptor (rhodopsin family): 7tm_1: G64-Y320	HMMER-PFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
7	7472432CD1	469	S207 S251 S264 S458	N168 N357 N94	transmembrane domain: M74-W93, L221-L241, L360-M378	HMMER
8	7474977CD1	372	S217 S27 S289 T116 T163		G-PROTEIN COUPLED RECEPTORS: DM00013|P31387|46-367: P46-T369	BLAST-DOMO
					5HYDROXYTRYPTAMINE 5B RECEPTOR: PD027821: M1-H84	BLAST-PRODOM
					G-protein coupled receptors: BL00237A: R120-H159 BL00237B: F222-Y233 BL00237C: Q293-T319 BL00237D: N345-N361	BLIMPS-BLOCKS
					Rhodopsin-like GPCR superfamily: PR00237A: L54-P78 PR00237B: P87-P108 PR00237C: H134-I156 PR00237D: A170-L191 PR00237E: A214-Y237 PR00237F: A298-I322 PR00237G: K335-N361	BLIMPS-PRINTS
					5-hydroxytryptamine 5B receptor: PR00519A: A3-P19 PR00519B: E20-P36 PR00519C: P36-V50 PR00519D: E196-R204 PR00519E: R246-V260 PR00519F: V262-V272	BLIMPS-PRINTS
					transmembrane domain: F48-L68, M300-L318	HMMER
					7 transmembrane receptor (rhodopsin family): 7tm_1: W69-Y353	HMMER-PFAM
					signal_cleavage: M1-A65	SPSCAN

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
9	7474848CD1	330	T125, S284, S161, S173	N271	G-protein coupled receptors signature: F105-L153	PROFILESCAN
					Rhodopsin-like GPCR superfamily: PR00237A: I32-G56; PR00237B: F64-N85; PR00237C: M109-V131; PR00237D: L145-K166; PR00237F: L221-L245; PR00237G:H261-K287	BLIMPS-PRINTS
					G-PROTEIN COUPLED RECEPTOR, TRANSMEMBRANE GLYCOPROTEIN: PD013244: F193-E309	BLAST-PRODOM
					G_Protein_Receptor (0210.pdoc): A115-V131	MOTIFS
					G-PROTEIN COUPLED RECEPTORS: DM00013|P04201|26-296: I32-Q288	BLAST-DOMO
					Transmembrane domain: I32-M59; C80-I97; Y113-W133; L145-I162; L191-C211; L218-G236	HMMER
					7 transmembrane receptor (rhodopsin family; 7tm_1): G47-Y279	HMMER-PFAM
					G-protein coupled receptor: BL00237A: C95-P134; BL00237B: T30-A41; BL00237C: L216-Q242; BL00237D: N271-K287	BLIMPS-BLOCKS
10	7655614CD1	494	S146, T266, T303, Y406	N54, N393	Rhodopsin-like GPCR superfamily: PR00237A: A105-V129; PR00237B: T138-A159; PR00237C: S191-I213; PR00237D: R225-L246; PR00237E: S278-C301; PR00237F: T329-L353; PR00237G: S369-S395	BLIMPS-PRINTS
					G-protein coupled receptor: BL00237A: A177-P216; BL00237B: Y286-H297; BL00237C: F324-L350; BL00237D: N379-S395	BLIMPS-BLOCKS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
10					RHODOPSIN GTP-BINDING: PD062404: A249-A330	BLAST-PRODOM
					G-PROTEIN COUPLED RECEPTORS: DM00013|P47211|27-319: L108-N393	BLAST-DOMO
					Transmembrane domain: L110-V129	HMMER
					7 transmembrane receptor (rhodopsin family; 7tm_1): G120-Y387	HMMER-PFAM
					G protein receptor (0210.pdoc): V197-I213	MOTIFS
					G-protein coupled receptors signature: F189-G239	PROFILESCAN
11	6792419CD1	532	S14 S25 S36 S395 S43 S480 S497 S503 S526 T189 T308 T361 Y520	N149 N2 N209	transmembrane domain: T189-I206, V313-M335, W365-M390	HMMER
					7 transmembrane receptor (rhodopsin family): G208-L476	HMMER-PFAM
					G_PROTEIN_RECEPTOR: BL00237A: W257-W296; BL00237B: F372-Y383; BL00237C: K406-S432; BL00237D: N468-K484	BLIMPS-BLOCKS
					Endothelin-B receptor signature: PR00571A: Q92-G110; PR00571B: G110-T127; PR00571C: P128-W144; PR00571D: R154-T174; PR00571E: D256-V267; PR00571F: H348-A362; PR00571G: F498-N516; PR00571H: D517-S531	BLIMPS-PRINTS
					Endothelin receptor signature: PR00366A: C180-C199; PR00366B: R214-P226; PR00366C: S295-E311; PR00366D: P325-G339; PR00366E: F355-C373; PR00366F: T379-G396; PR00366G: M397-V411	BLIMPS-PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
11					Bombesin receptor signature: PR00358A: D244-F259; PR00358B: K265-S281; PR00358C: V479-C492	BLIMPS-PRINTS
					G-protein coupled receptors signature: P268-I315	PROFILESCAN
					G_Protein_Receptor: I277-V293	MOTIFS
					RECEPTOR G PROTEIN COUPLED TRANSMEMBRANE ETB GLYCOPROTEIN ENDOTHELIN B PRECURSOR PD010509: M91-R166	BLAST-PRODOM
					RECEPTOR G PROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN SIGNAL ENDOTHELIN TYPE ETB PD004497: T167-C221	BLAST-PRODOM
					RECEPTOR G PROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN SIGNAL ENDOTHELIN TYPE B PD010472: L478-S532	BLAST-PRODOM
					G-PROTEIN COUPLED RECEPTORS DM00013|P28088|94-400: E185-L491 DM00013|P21450|74-385: E185-C492 DM00013|A54126|63-374: E185-C492 DM00013|P32940|82-398: E185-L491	BLAST-DOMO
12	7474790CD1	485	S210 S260 S273 S301 S308 S340 S356 S360 S460 T121 T302 T43 T437	N338	signal peptide: M1-A67	SPSCAN
					signal peptide: M1-A30	HMMER
					transmembrane domain: T13-L33, A83-S103, S168-Y189, I378-W401	HMMER
					7 transmembrane receptor (rhodopsin family): G25-Y431	HMMER-PFAM
					G_PROTEIN_RECEPTOR: BL00237A: W74-P113; BL00237B: I178-Y189; BL00237C: C369-L395; BL00237D: Q423-K439	BLIMPS-BLOCKS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
12					Rhodopsin-like GPCR superfamily signature: PR00237A: I10-Q34; PR00237B: T43-W64; PR00237C: T88-I110; PR00237D: R124-Y145; PR00237E: T170-F193; PR00237F: A374-L398; PR00237G: I413-K439	BLIMPS-PRINTS
					G-protein coupled receptors signature: L84-L129	PROFILESCAN
					G_Protein_Receptor: A94-I110	MOTIFS
					RECEPTOR COUPLED G PROTEIN TRANSMEMBRANE GLYCOPROTEIN PHOSPHORYLATION LIPOPROTEIN PALMITATE PROTEIN FAMILY PD000009: Q34-W147	BLAST-PRODOM
					G-PROTEIN COUPLED RECEPTORS DM00013: P18130|20-341: P2-Q199, K373-L446 P25100|90-417: A6-R208, K373-L446 P35368|39-364: I3-R198, N338-K440 P50407|76-400: A6-A201, I337-L446	BLAST-DOMO
13	7474816CD1	255		N145	transmembrane domain: Y37-L57	HMMER
					PHEROMONE RECEPTOR PD009900: L26-L247	BLAST-PRODOM
14	7476172CD1	881	S124 S130 S2 S303 S333 S636 S841 S879 T168 T169 T214 T407 T425 T461 T55 T613 T66	N212 N257 N285 N331 N38 N39 N405 N522 N545 N688 N74 N832 N865	transmembrane domains: I550-I569, F625-A642, Y657-W677, L705-F724	HMMER
					7 transmembrane receptor (metabotropic glutamate family): L548-N799	HMMER-PFAM
					Receptor family ligand binding region: F15-I456	HMMER-PFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
14					Metabotropic glutamate GPCR signature: PR00248B: V23-N38; PR00248C: I37-C56; PR00248D: V96-Y122; PR00248E: L129-Q148; PR00248F: Q148-I164; PR00248G: I164-F181; PR00248I: G622-F643; PR00248J: P659-A682; PR00248K: Y713-A736; PR00248L: N734-P755	BLIMPS-PRINTS
					RECEPTOR G PROTEIN COUPLED PHEROMONE METABOTROPIC GLUTAMATE PD001315: L661-N799, I550-K727	BLAST-PRODOM
					RECEPTOR SIGNAL PRECURSOR GLUTAMATE GLYCOPROTEIN MEMBRANE LYASE SUBUNIT IONIC PD001021: L28-I264, Y377-K433	BLAST-PRODOM
					G-PROTEIN COUPLED RECEPTORS FAMILY 3 DM00837: P35384|1-894: D513-T800, A29-T409 I59362|1-893: D513-T800, A29-D410 P31422|1-859: C517-S825, L25-K305 P31421|1-850: H525-S802, L25-I345	BLAST-DOMO
15	7472141CD1	309	S266 T87 T162 T291	N4	transmembrane domain: M58-L81 M29-V48	HMMER
					7 transmembrane receptor (rhodopsin family): G40-Y290	HMMER-PFAM
					G-protein coupled receptor BL00237A: K89-P128 BL00237D: T282-R298	BLIMPS-BLOCKS
					G-protein coupled receptors signature: F102-I147	PROFILESCAN
					G-protein coupled receptors signature: T109-I125	MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
15					Olfactory receptor signature PR00245A: M58-K79 PR00245B: F176-N190 PR00245C: L238-A253 PR00245D: I274-L285 PR00245E: T291-V305	BLIMPS-PRINTS
					RECEPTOR OLFACTORY PROTEIN G-PROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: L165-M246	BLAST-PRODOM
					OLFACTORY RECEPTOR PROTEIN G-PROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD149621: V247-R303	BLAST-PRODOM
					G-PROTEIN COUPLED RECEPTORS DM00013|P23274|18-306: I25-R303 DM00013|P23275|17-306: V16-R303 DM00013|P30955|18-305: I25-V305 DM00013|P23266|17-306: I25-V305	BLAST-DOMO
16	7472137CD1	224	S135 S191 S50 S65 S76	N3	Transmembrane domain: V27-A46, I133-T159, M195-I212	HMMER
					7 transmembrane receptor (rhodopsin family): G39-M144	HMMER-PFAM
					G-protein coupled receptors signature: F100-F149	PROFILESCAN
					G-protein coupled receptor domain BL00237: R88-P127	BLIMPS-BLOCKS
					Olfactory receptor signature PR00245: M57-K78, Y175-D189	BLIMPS-PRINTS
					Melanocortin receptor family PR00534: S49-L61, I124-S135 (P<0.004)	BLIMPS-PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
16					OLFACTORY RECEPTOR PROTEIN PD000921: L164-L224	BLAST-PRODOM
					G-PROTEIN COUPLED RECEPTORS DM00013|P30955|18-305: I24-L224	BLAST-DOMO
17	7477934CD1	326	S186 S20 S235 S289 S36 S65 T190 T191	N153 N5	7 transmembrane receptor (rhodopsin family) 7tm_1: E39-Y288	HMMER-PFAM
					G-PROTEIN COUPLED RECEPTORS DM00013|A57069|15-304: F33-L303	BLAST-DOMO
					RECEPTOR OLFACTORY PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: F166-I244	BLAST-PRODOM
					OLFACTORY RECEPTOR PROTEIN RECEPTORLIKE GPROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD149621: V245-F307	BLAST-PRODOM
					G-protein coupled receptor BL00237: R88-P127, L205-Y216, T280-L296	BLIMPS-BLOCKS
					Olfactory receptor signature PR00245: F236-G251, L272-L283, S289-L303, M57-K78, F175-D189	BLIMPS-PRINTS
					G-protein coupled receptors signature: F100-G145	PROFILESCAN
					transmembrane domain: L25-L46	HMMER
					G_Protein_Receptor: G108-I124	MOTIFS

Table 4

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
18	1714538CB1	2374	1-1852, 2139-2374, 1-234, 818-1572, 532-1151, 68-691	71687857V1	2141	2287
				71688177V1	986	1547
				71688995V1	1246	1843
				71687846V1	1684	2287
				1714538H1 (UCMCNOT02)	4	289
				GNN:g6855250_000025_002_edit	87	1365
				4516658H1 (SINJNOT03)	2113	2374
19	3406743CB1	813	1-168, 321-725	FL210313_00001	1	813
20	3485895CB1	1542	1-334, 626-883, 1518-1542	71296533V1	926	1542
				71755255V1	525	1186
				60149346D1	87	518
				GNN.g6479070_edit	1	300
				71295925V1	492	1180
21	7476102CB1	1191	1168-1191, 1-1097	GBI.g7684460_edit	1	1191
22	2432942CB1	3360	1-1940, 3316-3360, 2803-2843	2432516H1 (BRAVUNT02)	1	238
				70572441V1	1447	2041
				70254651V1	997	1498
				8116752H1 (TONSDIC01)	682	1314
				71733263V1	300	966
				71873820V1	2675	3360
				55046039J2	131	943
				6544942F6 (LNODNON02)	2018	2827
				71730213V1	2145	2854
				70815928V1	1502	2139
23	4630911CB1	1660	1-1260	2204242T6 (SPLNFET02)	1263	1660
				71047664V1	924	1516
				7706542J1 (UTRETUE01)	245	563
				GBI.g8112480.edit	1	1125
				6589031F8 (TLYMUNT03)	459	1158

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
24	7472432CB1	2603	1-24, 2540-2603, 838-2005	6975661H1 (BRAHTDR04)	1657	2249
				55037225J2	1	393
				7341002H1 (COLNDIN02)	2336	2603
				7059069H1 (BRALNON02)	1819	2477
				FL7472432CB1_00001	239	1648
				2964391F6 (SCORNOT04)	1353	1728
25	7474977CB1	1119	1-1119	g7137674_edit	1	1119
26	7474848CB1	1018	1-140, 262-344, 546-571, 992-1018	GBI.g8081257_edit	1	1018
35	7655614CB1.comp	2177	1537-2177, 1-39, 857-1072, 372-472	7655614H1 (UTREDME06)	653	1240
				FL7655614_g7406476_g156725	705	2177
				7655614J1 (UTREDME06)	1	710
28	6792419CB1	1632	1-234, 1-695, 752-809	6314367T6 (NERDTDN03)	811	1620
				6110713F8 (MCLDTXT03)	161	968
				g4580923_CD	1	1632
				70619934V1	1048	1624
29	7474790CB1	1458	1-103, 370-1458	GNN.g6759183_000017_002.edit	1	1458
30	7474816CB1	1015	1-489, 564-1015	55078072J1	1	596
				FL7474816_g8080066_000028_g1055254	248	1015
31	7476172CB1	2781	888-2781, 1-252, 1-393, 687-2781	FL7476172_g7684554_000005_g5809686	1	2781
32	7472141CB1	1267	1-449, 1-938	g7940222_edit	1	1267
33	7472137CB1	1559	1268-1559, 1-1043	FL7472137_g8118970_000006_g1256393	624	1559
				55033677H1 (FLP4X0017)	1	877
34	7477934CB1	981	43-92, 909-981	GBI.g8568403_000012.edit	1	981

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID	Representative Library
18	1714538CB1	BRSTNON02
19	3406743CB1	PROSTUS08
20	3485895CB1	KIDNNOT20
22	2432942CB1	BRAVUNT02
23	4630911CB1	SPLNFET02
24	7472432CB1	SCORNOT04
27	7655614CB1	PITUDIR01
28	6792419CB1	NERDTDN03

Table 6

Library	Vector	Library Description
BRAVUNT02	PSPORT1	Library was constructed using polyA RNA isolated from separate populations of unstimulated astrocytes. The RNA was pooled for polyA RNA isolation and library construction.
BRSTNON02	pINCY	This normalized breast tissue library was constructed from 6.2 million independent clones from a pool of two libraries from two different donors. Starting RNA was made from breast tissue removed from a 46-year-old Caucasian female during a bilateral reduction mammoplasty (donor A), and from breast tissue removed from a 60-year-old Caucasian female during a bilateral reduction mammoplasty (donor B). Pathology indicated normal breast parenchyma, bilaterally (A) and bilateral mammary hypertrophy (B). Patient history included hypertrophy of breast, obesity, lumbago, and glaucoma (A) and joint pain in the shoulder, thyroid cyst, colon cancer, normal delivery and cervical cancer (B). Family history included cataract, osteoarthritis, uterine cancer, benign hypertension, hyperlipidemia, and alcoholic cirrhosis of the liver, cerebrovascular disease, and type II diabetes (A) and cerebrovascular accident, atherosclerotic coronary artery disease, colon cancer, type II diabetes, hyperlipidemia, depressive disorder, and Alzheimer's Disease. The library was normalized in two rounds using conditions adapted from Soares et al. (1994) PNAS 91:9228-9232 and Bonaldo et al. (1996) Genome Research 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used.
KIDNNOT20	pINCY	Library was constructed using RNA isolated from left kidney tissue removed from a 43-year-old Caucasian male during nephroureterectomy, regional lymph node excision, and unilateral left adrenalectomy. Pathology for the associated tumor tissue indicated a grade 2 renal cell carcinoma. Family history included atherosclerotic coronary artery disease.
PITUDIR01	PCDNA2.1	This random primed library was constructed using RNA isolated from pituitary gland tissue removed from a 70-year-old female who died from metastatic adenocarcinoma. Pathology for the brain indicated moderate Alzheimer disease and mild carotid and cerebral atherosclerosis. The cerebral hemispheres, frontal and temporal lobes, white matter, and hippocampus showed mild atrophy, bilaterally. There were numerous neurofibrillary tangles, neuritic and diffuse amyloid plaques deposited throughout most neocortical areas.
SPLNFET02	pINCY	Library was constructed using RNA isolated from spleen tissue removed from a Caucasian male fetus, who died at 23 weeks' gestation.

Table 6 (cont.)

Library	Vector	Library Description
NERDTDN03	pINCY	This normalized dorsal root ganglion tissue library was constructed from 1.05 million independent clones from a dorsal root ganglion tissue library. Starting RNA was made from dorsal root ganglion tissue removed from the cervical spine of a 32-year-old Caucasian male who died from acute pulmonary edema, acute bronchopneumonia, bilateral pleural effusions, pericardial effusion, and malignant lymphoma (natural killer cell type). The patient presented with pyrexia of unknown origin, malaise, fatigue, and gastrointestinal bleeding. Patient history included probable cytomegalovirus infection, liver congestion, and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, respiratory failure, pneumonia of the left lung, natural killer cell lymphoma of the pharynx, Bell's palsy, and tobacco and alcohol abuse. Previous surgeries included colonoscopy, closed colon biopsy, adenotonsillectomy, and nasopharyngeal endoscopy and biopsy. Patient medications included Diflucan (fluconazole), Deltasone (prednisone), hydrocodone, Lortab, Alprazolam, Reazodone, ProMace-Cytabom, Etoposide, Cisplatin, Cytarabine, and dexamethasone. The patient received radiation therapy and multiple blood transfusions. The library was normalized in 2 rounds using conditions adapted from Soares et al. (1994) PNAS 91:9228-9232 and Bonaldo et al. (1996) Genome Research 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used.
PROSTUS08	PT7T3	This subtracted library was constructed using 2.36 million clones from a prostate tumor library and was subjected to one round of subtractive hybridization with 448,000 clones from a normal prostate library. The starting library for subtraction was constructed using RNA isolated from a prostate tumor removed from a 59-year-old Caucasian male during a radical prostatectomy with regional lymph node excision. Pathology indicated adenocarcinoma (Gleason grade 3+3) Adenofibromatous hyperplasia was present. The patient presented with elevated prostate-specific antigen (PSA). Patient history included colon diverticuli, asbestosis, and thrombophlebitis. Family history included multiple myeloma, hyperlipidemia, and rheumatoid arthritis. Subtractive hybridization conditions were based on the methodologies of Swaroop et al. (1991) NAR 19:1954 and Bonaldo et al. (1996) Genome Research 6:791.
SCORNOT04	pINCY	Library was constructed using RNA isolated from cervical spinal cord tissue removed from a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus, infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy. Surgeries included colonoscopy, large intestine biopsy, adenotonsillectomy, and nasopharyngeal endoscopy and biopsy; treatment included radiation therapy.

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	*ESTs:* Probability value= 1.0E-8 or less *Full Length sequences*: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises as least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	*ESTs:* fasta E value=1.06E-6 *Assembled ESTs*: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less *Full Length sequences:* fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	*PFAM hits:* Probability value= 1.0E-3 or less *Signal peptide hits:* Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score≥GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

Table 8

Tissues	Polynucleotide SEQ ID NO: 33
Breast, Fat, Skin	-
Muscle, Bone, Synovium, Connective tissue	+
Pancreas, Liver, Gallbladder	-
Brain: Amygdala, Thalamus, Hippocampus, Entorhinal cortex, Archaecortex	-
Brain: Striatum, Caudate nucleus, Putamen, Dentate nucleus, Globus pallidus, Substantia innominata, Ralphe magnus	-
Kidney, Fetal colon, Small intestine, Ileum, Esophagus	-
Fetal heart, Aorta, Coronary artery	-
Fetal lung, Adult lung	-
Placenta, Prostate, Uterus	-
Olfactory bulb	-

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:

a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-17,

b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-17,

c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, and

d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17.

2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-17.

3. An isolated polynucleotide encoding a polypeptide of claim 1.

4. An isolated polynucleotide encoding a polypeptide of claim 2.

5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:18-34.

6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

7. A cell transformed with a recombinant polynucleotide of claim 6.

8. A transgenic organism comprising a recombinant polynucleotide of claim 6.

9. A method for producing a polypeptide of claim 1, the method comprising:

a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

b) recovering the polypeptide so expressed.

10. An isolated antibody which specifically binds to a polypeptide of claim 1.

11. An isolated polynucleotide selected from the group consisting of:

a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:18-34,

b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:18-34,

c) a polynucleotide complementary to a polynucleotide of a),

d) a polynucleotide complementary to a polynucleotide of b), and

e) an RNA equivalent of a)-d).

12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and

b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and

b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

16. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

17. A composition of claim 16, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-17.

18. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition of claim 16.

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting agonist activity in the sample.

20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

21. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 20.

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting antagonist activity in the sample.

23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

24. A method for treating a disease or condition associated with overexpression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 23.

25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and

b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,

b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and

c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,

b) detecting altered expression of the target polynucleotide, and

c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

28. A method for assessing toxicity of a test compound, said method comprising:

a) treating a biological sample containing nucleic acids with the test compound;

b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;

c) quantifying the amount of hybridization complex; and

d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the

amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

29. A diagnostic test for a condition or disease associated with the expression of GCREC in a biological sample comprising the steps of:

a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and

b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

30. The antibody of claim 10, wherein the antibody is:

a) a chimeric antibody,

b) a single chain antibody,

c) a Fab fragment,

d) a $F(ab')_2$ fragment, or

e) a humanized antibody.

31. A composition comprising an antibody of claim 10 and an acceptable excipient.

32. A method of diagnosing a condition or disease associated with the expression of GCREC in a subject, comprising administering to said subject an effective amount of the composition of claim 31.

33. A composition of claim 31, wherein the antibody is labeled.

34. A method of diagnosing a condition or disease associated with the expression of GCREC in a subject, comprising administering to said subject an effective amount of the composition of claim 33.

35. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 10 comprising:

a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, or an immunogenic fragment thereof, under conditions to elicit an antibody response;

b) isolating antibodies from said animal; and

c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17.

36. An antibody produced by a method of claim 35.

37. A composition comprising the antibody of claim 36 and a suitable carrier.

38. A method of making a monoclonal antibody with the specificity of the antibody of claim 10 comprising:

a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17, or an immunogenic fragment thereof, under conditions to elicit an antibody response;

b) isolating antibody producing cells from the animal;

c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;

d) culturing the hybridoma cells; and

e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17.

39. A monoclonal antibody produced by a method of claim 38.

40. A composition comprising the antibody of claim 39 and a suitable carrier.

41. The antibody of claim 10, wherein the antibody is produced by screening a Fab expression library.

42. The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.

43. A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17 in a sample, comprising the steps of:

a) incubating the antibody of claim 10 with a sample under conditions to allow specific

binding of the antibody and the polypeptide; and

b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17 in the sample.

44. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17 from a sample, the method comprising:

a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-17.

45. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

46. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

47. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

48. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

49. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

50. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

51. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

52. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

53. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.

54. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.

55. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.

56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.

57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.

58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.

59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.

60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.

61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17

62. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:18.

63. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:19.

64. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:20.

65. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:21.

66. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:22.

67. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:23.

68. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:24.

69. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID

NO:25.

70. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:26.

71. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:27.

72. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:28.

73. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:29.

74. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:30.

75. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:31.

76. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:32.

77. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:33.

78. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:34.

<110> INCYTE GENOMICS, INC.
LAL, Preeti
BAUGHN, Mariah R.
HAFALIA, April J. A.
NGUYEN, Danniel B.
GANDHI, Ameena R.
KALLICK, Deborah A.
GRIFFIN, Jennifer A.
YUE, Henry
KHAN, Farrah A.
PATTERSON, Chandra
LU, Dyung Aina M.
TRIBOULEY, Catherine M.
LU, Yan
WALIA, Narinder K.
GRAUL, Richard
YAO, Monique G.
YANG, Junming
RAMKUMAR, Jayalaxmi
AU-YOUNG, Janice
ELLIOTT, Vicki S.
HERNANDEZ, Roberto
WALSH, Roderick T.
BOROWSKY, Mark L.
THORNTON, Michael
HE, Ann

<120> G-PROTEIN COUPLED RECEPTORS

<130> PI-0131 PCT

<140> To Be Assigned
<141> Herewith

<150> 60/212,483; 60/213,954; 60/215,209; 60/216,595; 60/218,936;
60/219,154; 60/220,141
<151> 2000-06-16; 2000-06-22; 2000-06-29; 2000-07-07; 2000-07-14;
2000-07-19; 2000-07-21

<160> 35
<170> PERL Program

<210> 1
<211> 426
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1714538CD1

<400> 1
Met Thr Pro Leu Cys Leu Asn Cys Ser Val Leu Pro Gly Asp Leu
1 5 10 15
Tyr Pro Gly Gly Ala Arg Asn Pro Met Ala Cys Asn Gly Ser Ala
20 25 30
Ala Arg Gly His Phe Asp Pro Glu Asp Leu Asn Leu Thr Asp Glu
35 40 45
Ala Leu Arg Leu Lys Tyr Leu Gly Pro Gln Gln Thr Glu Leu Phe
50 55 60
Met Pro Ile Cys Ala Thr Tyr Leu Leu Ile Phe Val Val Gly Ala
65 70 75

```
Val Gly Asn Gly Leu Thr Cys Leu Val Ile Leu Arg His Lys Ala
                 80                  85                  90
Met Arg Thr Pro Thr Asn Tyr Tyr Leu Phe Ser Leu Ala Val Ser
                 95                 100                 105
Asp Leu Leu Val Leu Leu Val Gly Leu Pro Leu Glu Leu Tyr Glu
                110                 115                 120
Met Trp His Asn Tyr Pro Phe Leu Leu Gly Val Gly Gly Cys Tyr
                125                 130                 135
Phe Arg Thr Leu Leu Phe Glu Met Val Cys Leu Ala Ser Val Leu
                140                 145                 150
Asn Val Thr Ala Leu Ser Val Glu Arg Tyr Val Ala Val Val His
                155                 160                 165
Pro Leu Gln Ala Arg Ser Met Val Thr Arg Ala His Val Arg Arg
                170                 175                 180
Val Leu Gly Ala Val Trp Gly Leu Ala Met Leu Cys Ser Leu Pro
                185                 190                 195
Asn Thr Ser Leu His Gly Ile Arg Gln Leu His Val Pro Cys Arg
                200                 205                 210
Gly Pro Val Pro Asp Ser Ala Val Cys Met Leu Val Arg Pro Arg
                215                 220                 225
Ala Leu Tyr Asn Met Val Val Gln Thr Thr Ala Leu Leu Phe Phe
                230                 235                 240
Cys Leu Pro Met Ala Ile Met Ser Val Leu Cys Leu Leu Val Gly
                245                 250                 255
Leu Arg Leu Arg Arg Glu Arg Leu Leu Leu Met Gln Glu Ala Lys
                260                 265                 270
Gly Arg Gly Ser Ala Ala Ala Arg Ser Arg Tyr Thr Cys Arg Leu
                275                 280                 285
Gln Gln His Asp Arg Gly Arg Gly Gln Val Thr Lys Met Leu Phe
                290                 295                 300
Val Leu Val Val Val Phe Gly Ile Cys Trp Ala Pro Phe His Ala
                305                 310                 315
Asp Arg Val Met Trp Ser Val Val Ser Gln Trp Thr Asp Gly Leu
                320                 325                 330
His Leu Ala Phe Gln His Val His Val Ile Ser Gly Ile Phe Phe
                335                 340                 345
Tyr Leu Gly Ser Ala Ala Asn Pro Val Leu Tyr Ser Leu Met Ser
                350                 355                 360
Ser Arg Phe Arg Glu Thr Phe Gln Glu Ala Leu Cys Leu Gly Ala
                365                 370                 375
Cys Cys His Arg Leu Arg Pro Arg His Ser Ser His Ser Leu Ser
                380                 385                 390
Arg Met Thr Thr Gly Ser Thr Leu Cys Asp Val Gly Ser Leu Gly
                395                 400                 405
Ser Trp Val His Pro Leu Ala Gly Asn Asp Gly Pro Glu Ala Gln
                410                 415                 420
Gln Glu Thr Asp Pro Ser
                425

<210> 2
<211> 259
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3406743CD1

<400> 2
Met Glu Asp Leu Phe Ser Pro Ser Ile Leu Pro Pro Ala Pro Asn
  1                 5                  10                  15
Ile Ser Val Pro Ile Leu Leu Gly Trp Gly Leu Asn Leu Thr Leu
                 20                  25                  30
```

```
Gly Gln Gly Ala Pro Ala Ser Gly Pro Pro Ser Arg Arg Val Arg
                35                  40                  45
Leu Val Phe Leu Gly Val Ile Leu Val Val Ala Val Ala Gly Asn
                50                  55                  60
Thr Thr Val Leu Cys Arg Leu Cys Gly Gly Gly Gly Pro Trp Ala
                65                  70                  75
Gly Pro Lys Arg Arg Lys Met Asp Phe Leu Leu Val Gln Leu Ala
                80                  85                  90
Leu Ala Asp Leu Tyr Ala Cys Gly Gly Thr Ala Leu Ser Gln Leu
                95                  100                 105
Ala Trp Glu Leu Leu Gly Glu Pro Arg Ala Ala Thr Gly Asp Leu
                110                 115                 120
Ala Cys Arg Phe Leu Gln Leu Leu Gln Ala Ser Gly Arg Gly Ala
                125                 130                 135
Ser Ala His Leu Val Val Leu Ile Ala Leu Glu Arg Arg Arg Ala
                140                 145                 150
Pro Gly Ala Pro Leu Ser Ala Arg Ala Trp Pro Gly Met Arg Arg
                155                 160                 165
Cys His Trp Ile Phe Ala Leu Leu Gln Arg Trp His Val Gln Val
                170                 175                 180
Tyr Ala Phe Tyr Glu Ala Val Ala Gly Phe Val Ala Pro Val Lys
                185                 190                 195
Ile Met Gly Val Ala Cys Gly His Leu Leu Ser Val Trp Trp Arg
                200                 205                 210
His Arg Leu Lys Ala Pro Ala Gly Ala Ala Ala Trp Ser Ala Ser
                215                 220                 225
Pro Gly Gly Ala Arg Ala Pro Ser Ala Met Pro Arg Ala Lys Val
                230                 235                 240
Gln Ser Leu Lys Met Ser Gln Leu Leu Gly Leu Leu Phe Val Gly
                245                 250                 255
Cys Glu Leu Pro
```

<210> 3
<211> 379
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3485895CD1

<400> 3

```
Met Gln Ile Gly His Leu Ala Gln His Trp Val Arg Ser Tyr Ile
  1                 5                  10                  15
Gln Leu Leu Ala Glu Phe Leu Ser Arg Asp Gln Val Phe Gln Gln
                20                  25                  30
Asn Gly Tyr Gly Leu Thr Gln Gln Asn Leu Leu Asn Asn Tyr Asp
                35                  40                  45
Met Leu Gly Ile Met Ala Trp Asn Ala Thr Cys Lys Asn Trp Leu
                50                  55                  60
Ala Ala Glu Ala Ala Leu Glu Lys Tyr Tyr Leu Ser Ile Phe Tyr
                65                  70                  75
Gly Ile Glu Phe Val Val Gly Val Leu Gly Asn Thr Ile Val Val
                80                  85                  90
Tyr Gly Tyr Ile Phe Ser Leu Lys Asn Trp Asn Ser Ser Asn Ile
                95                  100                 105
Tyr Leu Phe Asn Leu Ser Val Ser Asp Leu Ala Phe Leu Cys Thr
                110                 115                 120
Leu Pro Met Leu Ile Arg Ser Tyr Ala Asn Gly Asn Trp Ile Tyr
                125                 130                 135
Gly Asp Val Leu Cys Ile Ser Asn Arg Tyr Val Leu His Ala Asn
                140                 145                 150
```

```
Leu Tyr Thr Ser Ile Leu Phe Leu Thr Phe Ile Ser Ile Asp Arg
                155                 160                 165
Tyr Leu Ile Ile Lys Tyr Pro Phe Arg Glu His Leu Leu Gln Lys
                170                 175                 180
Lys Glu Phe Ala Ile Leu Ile Ser Leu Ala Ile Trp Val Leu Val
                185                 190                 195
Thr Leu Glu Leu Leu Pro Ile Leu Pro Leu Ile Asn Pro Val Ile
                200                 205                 210
Thr Asp Asn Gly Thr Thr Cys Asn Asp Phe Ala Ser Ser Gly Asp
                215                 220                 225
Pro Asn Tyr Asn Leu Ile Tyr Ser Met Cys Leu Thr Leu Leu Gly
                230                 235                 240
Phe Leu Ile Pro Leu Phe Val Met Cys Phe Phe Tyr Tyr Lys Ile
                245                 250                 255
Ala Leu Phe Leu Lys Gln Arg Asn Arg Gln Val Ala Thr Ala Leu
                260                 265                 270
Pro Leu Glu Lys Pro Leu Asn Leu Val Ile Met Ala Val Val Ile
                275                 280                 285
Phe Ser Val Leu Phe Thr Pro Tyr His Val Met Arg Asn Val Arg
                290                 295                 300
Ile Ala Ser Arg Leu Gly Ser Trp Lys Gln Tyr Gln Cys Thr Gln
                305                 310                 315
Val Val Ile Asn Ser Phe Tyr Ile Val Thr Arg Pro Leu Ala Phe
                320                 325                 330
Leu Asn Ser Val Ile Asn Pro Val Phe Tyr Phe Leu Leu Gly Asp
                335                 340                 345
His Phe Arg Asp Met Leu Met Asn Gln Leu Arg His Asn Phe Lys
                350                 355                 360
Ser Leu Thr Ser Phe Ser Arg Trp Ala His Glu Leu Leu Leu Ser
                365                 370                 375
Phe Arg Glu Lys
```

<210> 4
<211> 396
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7476102CD1

<400> 4

```
Met Gly Asp Glu Leu Ala Pro Cys Pro Val Gly Thr Thr Ala Trp
  1               5                  10                  15
Pro Ala Leu Ile Gln Leu Ile Ser Lys Thr Pro Cys Met Pro Gln
                20                  25                  30
Ala Ala Ser Asn Thr Ser Leu Gly Leu Gly Asp Leu Arg Val Pro
                35                  40                  45
Ser Ser Met Leu Tyr Trp Leu Phe Leu Pro Ser Ser Leu Leu Ala
                50                  55                  60
Ala Ala Thr Leu Ala Val Ser Pro Leu Leu Leu Val Thr Ile Leu
                65                  70                  75
Arg Asn Gln Arg Leu Arg Gln Glu Pro His Tyr Leu Leu Pro Ala
                80                  85                  90
Asn Ile Leu Leu Ser Asp Leu Ala Tyr Ile Leu Leu His Met Leu
                95                 100                 105
Ile Ser Ser Ser Ser Leu Gly Gly Trp Glu Leu Gly Arg Met Ala
                110                 115                 120
Cys Gly Ile Leu Thr Asp Ala Val Phe Ala Ala Cys Thr Ser Thr
                125                 130                 135
Ile Leu Ser Phe Thr Ala Ile Val Leu His Thr Tyr Leu Ala Val
                140                 145                 150
```

```
Ile His Pro Leu Arg Tyr Leu Ser Phe Met Ser His Gly Ala Ala
                155                 160                 165
Trp Lys Ala Val Ala Leu Ile Trp Leu Val Ala Cys Cys Phe Pro
                170                 175                 180
Thr Phe Leu Ile Trp Leu Ser Lys Trp Gln Asp Ala Gln Leu Glu
                185                 190                 195
Glu Gln Gly Ala Ser Tyr Ile Leu Pro Pro Ser Met Gly Thr Gln
                200                 205                 210
Pro Gly Cys Gly Leu Leu Val Ile Val Thr Tyr Thr Ser Ile Leu
                215                 220                 225
Cys Val Leu Phe Leu Cys Thr Ala Leu Ile Ala Asn Cys Phe Trp
                230                 235                 240
Arg Ile Tyr Ala Glu Ala Lys Thr Ser Gly Ile Trp Gly Gln Gly
                245                 250                 255
Tyr Ser Arg Ala Arg Gly Thr Leu Leu Ile His Ser Val Leu Ile
                260                 265                 270
Thr Leu Tyr Val Ser Thr Gly Val Val Phe Ser Leu Asp Met Val
                275                 280                 285
Leu Thr Arg Tyr His His Ile Asp Ser Gly Thr His Thr Trp Leu
                290                 295                 300
Leu Ala Ala Asn Ser Glu Val Leu Met Met Leu Pro Arg Ala Met
                305                 310                 315
Leu Thr Tyr Leu Tyr Leu Leu Arg Tyr Arg Gln Leu Leu Gly Met
                320                 325                 330
Val Arg Gly His Leu Pro Ser Arg Arg His Gln Ala Ile Phe Thr
                335                 340                 345
Ile Ser Cys Cys Trp Glu Pro Leu Phe Tyr Phe Ser Leu Ile Leu
                350                 355                 360
Thr Thr Leu Gly Val Asp Ile Ile Pro Leu Cys Val Glu Thr Thr
                365                 370                 375
Phe Cys Leu Ser Ile His Leu Ser Met Asp Arg Leu Gly Cys Thr
                380                 385                 390
Thr Phe Gly Tyr Cys Glu
                395
```

<210> 5
<211> 528
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2432942CD1

<400> 5

```
Met Asp His Cys Gly Ala Leu Phe Leu Cys Leu Cys Leu Leu Thr
  1                 5                  10                  15
Leu Gln Asn Ala Thr Thr Glu Thr Trp Glu Glu Leu Leu Ser Tyr
                20                  25                  30
Met Glu Asn Met Gln Val Ser Arg Gly Arg Ser Ser Val Phe Ser
                35                  40                  45
Ser Arg Gln Leu His Gln Leu Glu Gln Met Leu Leu Asn Thr Ser
                50                  55                  60
Phe Pro Gly Tyr Asn Leu Thr Leu Gln Thr Pro Thr Ile Gln Ser
                65                  70                  75
Leu Ala Phe Lys Leu Ser Cys Asp Phe Ser Gly Leu Ser Leu Thr
                80                  85                  90
Ser Ala Thr Leu Lys Arg Val Pro Gln Ala Gly Gly Gln His Ala
                95                 100                 105
Arg Gly Gln His Ala Met Gln Phe Pro Ala Glu Leu Thr Arg Asp
               110                 115                 120
Ala Cys Lys Thr Arg Pro Arg Glu Leu Arg Leu Ile Cys Ile Tyr
               125                 130                 135
```

```
Phe Ser Asn Thr His Phe Phe Lys Asp Glu Asn Asn Ser Ser Leu
                140                 145                 150
Leu Asn Asn Tyr Val Leu Gly Ala Gln Leu Ser His Gly His Val
                155                 160                 165
Asn Asn Leu Arg Asp Pro Val Asn Ile Ser Phe Trp His Asn Gln
                170                 175                 180
Ser Leu Glu Gly Tyr Thr Leu Thr Cys Val Phe Trp Lys Glu Gly
                185                 190                 195
Ala Arg Lys Gln Pro Trp Gly Gly Trp Ser Pro Glu Gly Cys Arg
                200                 205                 210
Thr Glu Gln Pro Ser His Ser Gln Val Leu Cys Arg Cys Asn His
                215                 220                 225
Leu Thr Tyr Phe Ala Val Leu Met Gln Leu Ser Pro Ala Leu Val
                230                 235                 240
Pro Ala Glu Leu Leu Ala Pro Leu Thr Tyr Ile Ser Leu Val Gly
                245                 250                 255
Cys Ser Ile Ser Ile Val Ala Ser Leu Ile Thr Val Leu Leu His
                260                 265                 270
Phe His Phe Arg Lys Gln Ser Asp Ser Leu Thr Arg Ile His Met
                275                 280                 285
Asn Leu His Ala Ser Val Leu Leu Leu Asn Ile Ala Phe Leu Leu
                290                 295                 300
Ser Pro Ala Phe Ala Met Ser Pro Val Pro Gly Ser Ala Cys Thr
                305                 310                 315
Ala Leu Ala Ala Ala Leu His Tyr Ala Leu Leu Ser Cys Leu Thr
                320                 325                 330
Trp Met Ala Ile Glu Gly Phe Asn Leu Tyr Leu Leu Leu Gly Arg
                335                 340                 345
Val Tyr Asn Ile Tyr Ile Arg Arg Tyr Val Phe Lys Leu Gly Val
                350                 355                 360
Leu Gly Trp Gly Ala Pro Ala Leu Leu Val Leu Leu Ser Leu Ser
                365                 370                 375
Val Lys Ser Ser Val Tyr Gly Pro Cys Thr Ile Pro Val Phe Asp
                380                 385                 390
Ser Trp Glu Asn Gly Thr Gly Phe Gln Asn Met Ser Ile Cys Trp
                395                 400                 405
Val Arg Ser Pro Val Val His Ser Val Leu Val Met Gly Tyr Gly
                410                 415                 420
Gly Leu Thr Ser Leu Phe Asn Leu Val Val Leu Ala Trp Ala Leu
                425                 430                 435
Trp Thr Leu Arg Arg Leu Arg Glu Arg Ala Asp Ala Pro Ser Val
                440                 445                 450
Arg Ala Cys His Asp Thr Val Thr Val Leu Gly Leu Thr Val Leu
                455                 460                 465
Leu Gly Thr Thr Trp Ala Leu Ala Phe Phe Ser Phe Gly Val Phe
                470                 475                 480
Leu Leu Pro Gln Leu Phe Leu Phe Thr Ile Leu Asn Ser Leu Tyr
                485                 490                 495
Gly Phe Phe Leu Phe Leu Trp Phe Cys Ser Gln Arg Cys Arg Ser
                500                 505                 510
Glu Ala Glu Ala Lys Ala Gln Ile Glu Ala Phe Ser Ser Ser Gln
                515                 520                 525
Thr Thr Gln
```

<210> 6
<211> 361
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4630911CD1

<400> 6
Met Asn Arg Lys Gln Leu Glu Val Ile Pro Met Ile Trp Val Ile
1 5 10 15
Ser Leu Asp Lys Ser Lys Gly Thr Phe His Ile Gly Ser His Phe
20 25 30
Thr Ser Thr Ser Leu Ile Phe Ser Asn Cys Thr Asn Thr Asp Phe
35 40 45
Arg Tyr Phe Ile Tyr Ala Val Thr Tyr Thr Val Ile Leu Val Pro
50 55 60
Gly Leu Ile Gly Asn Ile Leu Ala Leu Trp Val Phe Tyr Gly Tyr
65 70 75
Met Lys Glu Thr Lys Arg Ala Val Ile Phe Met Ile Asn Leu Ala
80 85 90
Ile Ala Asp Leu Leu Gln Val Leu Ser Leu Pro Leu Arg Ile Phe
95 100 105
Tyr Tyr Leu Asn His Asp Trp Pro Phe Gly Pro Gly Leu Cys Met
110 115 120
Phe Cys Phe Tyr Leu Lys Tyr Val Asn Met Tyr Ala Ser Ile Tyr
125 130 135
Phe Leu Val Cys Ile Ser Val Arg Arg Phe Trp Phe Leu Met Tyr
140 145 150
Pro Phe Arg Phe His Asp Cys Lys Gln Lys Tyr Asp Leu Tyr Ile
155 160 165
Ser Ile Ala Gly Trp Leu Ile Ile Cys Leu Ala Cys Val Leu Phe
170 175 180
Pro Leu Leu Arg Thr Ser Asp Asp Thr Pro Gly Asn Arg Thr Lys
185 190 195
Cys Phe Val Asp Leu Pro Thr Arg Asn Val Asn Leu Ala Gln Ser
200 205 210
Val Val Met Met Thr Ile Gly Glu Leu Ile Gly Phe Val Thr Pro
215 220 225
Leu Leu Ile Val Leu Tyr Cys Thr Trp Lys Thr Val Leu Ser Leu
230 235 240
Gln Asp Lys Tyr Pro Met Ala Gln Asp Leu Gly Glu Lys Gln Lys
245 250 255
Ala Leu Lys Met Ile Leu Thr Cys Ala Gly Val Phe Leu Ile Cys
260 265 270
Phe Ala Pro Tyr His Phe Ser Phe Pro Leu Asp Phe Leu Val Lys
275 280 285
Ser Asn Glu Ile Lys Ser Cys Leu Ala Arg Arg Val Ile Leu Ile
290 295 300
Phe His Ser Val Ala Leu Cys Leu Ala Ser Leu Asn Ser Cys Leu
305 310 315
Asp Pro Val Ile Tyr Tyr Phe Ser Thr Asn Glu Phe Arg Arg Arg
320 325 330
Leu Ser Arg Gln Asp Leu His Asp Ser Ile Gln Leu His Ala Lys
335 340 345
Ser Phe Val Ser Asn His Thr Ala Ser Thr Met Thr Pro Glu Leu
350 355 360
Cys

<210> 7
<211> 469
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472432CD1

<400> 7
Met Ala Phe Leu Met His Leu Leu Val Cys Val Phe Gly Met Gly

```
  1               5                  10                  15
Ser Trp Val Thr Ile Asn Gly Leu Trp Val Glu Leu Pro Leu Leu
             20                  25                  30
Val Met Glu Leu Pro Glu Gly Trp Tyr Leu Pro Ser Tyr Leu Thr
         35                  40                  45
Val Val Ile Gln Leu Ala Asn Ile Gly Pro Leu Leu Val Thr Leu
     50                  55                  60
Leu His His Phe Arg Pro Ser Cys Leu Ser Glu Val Pro Met Ile
 65                  70                  75
Phe Thr Leu Leu Gly Val Gly Thr Val Thr Cys Ile Ile Phe Ala
             80                  85                  90
Phe Leu Trp Asn Met Thr Ser Trp Val Leu Asp Gly His His Ser
         95                  100                 105
Ile Ala Phe Leu Val Leu Thr Phe Phe Leu Ala Leu Val Asp Cys
    110                 115                 120
Thr Ser Ser Val Thr Phe Leu Pro Phe Met Ser Arg Leu Pro Thr
    125                 130                 135
Tyr Tyr Leu Thr Thr Phe Phe Val Gly Glu Gly Leu Ser Gly Leu
    140                 145                 150
Leu Pro Ala Leu Val Ala Leu Ala Gln Gly Ser Gly Leu Thr Thr
    155                 160                 165
Cys Val Asn Val Thr Glu Ile Ser Asp Ser Val Pro Ser Pro Val
    170                 175                 180
Pro Thr Arg Glu Thr Asp Ile Ala Gln Gly Val Pro Arg Ala Leu
    185                 190                 195
Val Ser Ala Leu Pro Gly Met Glu Ala Pro Leu Ser His Leu Glu
    200                 205                 210
Ser Arg Tyr Leu Pro Ala His Phe Ser Pro Leu Val Phe Phe Leu
    215                 220                 225
Leu Leu Ser Ile Met Met Ala Cys Cys Leu Val Ala Phe Phe Val
    230                 235                 240
Leu Gln Arg Gln Pro Arg Cys Trp Glu Ala Ser Val Glu Asp Leu
    245                 250                 255
Leu Asn Asp Gln Val Thr Leu His Ser Ile Arg Pro Arg Glu Glu
    260                 265                 270
Asn Asp Leu Gly Pro Ala Gly Thr Val Asp Ser Ser Gln Gly Gln
    275                 280                 285
Gly Tyr Leu Glu Glu Lys Ala Ala Pro Cys Cys Pro Ala His Leu
    290                 295                 300
Ala Phe Ile Tyr Thr Leu Val Ala Phe Val Asn Ala Leu Thr Asn
    305                 310                 315
Gly Met Leu Pro Ser Val Gln Thr Tyr Ser Cys Leu Ser Tyr Gly
    320                 325                 330
Pro Val Ala Tyr His Leu Ala Ala Thr Leu Ser Ile Val Ala Asn
    335                 340                 345
Pro Leu Ala Ser Leu Val Ser Met Phe Leu Pro Asn Arg Ser Leu
    350                 355                 360
Leu Phe Leu Gly Val Leu Ser Val Leu Gly Thr Cys Phe Gly Gly
    365                 370                 375
Tyr Asn Met Ala Met Ala Val Met Ser Pro Cys Pro Leu Leu Gln
    380                 385                 390
Gly His Trp Gly Gly Glu Val Leu Ile Val Ala Ser Trp Val Leu
    395                 400                 405
Phe Ser Gly Cys Leu Ser Tyr Val Lys Val Met Leu Gly Val Val
    410                 415                 420
Leu Arg Asp Leu Ser Arg Ser Ala Leu Leu Trp Cys Gly Ala Ala
    425                 430                 435
Val Gln Leu Gly Ser Leu Leu Gly Ala Leu Leu Met Phe Pro Leu
    440                 445                 450
Val Asn Val Leu Arg Leu Phe Ser Ser Ala Asp Phe Cys Asn Leu
    455                 460                 465
His Cys Pro Ala
```

<210> 8
<211> 372
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474977CD1

<400> 8
Met Glu Ala Ala Ser Leu Ser Val Ala Thr Ala Gly Val Ala Leu
1 5 10 15
Ala Leu Gly Pro Glu Thr Ser Ser Gly Thr Pro Ser Pro Arg Gly
20 25 30
Ile Leu Gly Ser Thr Pro Ser Gly Ala Val Leu Pro Gly Arg Gly
35 40 45
Pro Pro Phe Ser Val Phe Thr Val Leu Val Val Thr Leu Leu Val
50 55 60
Leu Leu Ile Ala Ala Thr Phe Leu Trp Asn Leu Leu Val Pro Val
65 70 75
Thr Ile Pro Arg Val Arg Ala Phe His Arg Val Pro His Asn Leu
80 85 90
Val Ala Ser Thr Ala Val Ser Asp Glu Leu Val Ala Ala Leu Ala
95 100 105
Met Pro Pro Ser Leu Ala Ser Glu Leu Ser Thr Gly Arg Arg Arg
110 115 120
Leu Leu Gly Arg Ser Leu Cys His Val Trp Ile Ser Phe His Val
125 130 135
Leu Cys Cys Pro Ala Gly Leu Gly Asn Val Ala Ala Ile Ala Leu
140 145 150
Gly Arg Asp Gly Ala Ile Thr Arg His Leu Gln His Thr Leu Arg
155 160 165
Thr Arg Ser Arg Ala Ser Leu Leu Met Ile Ala Leu Thr Arg Val
170 175 180
Pro Ser Ala Leu Ile Ala Leu Ala Pro Leu Leu Phe Gly Arg Gly
185 190 195
Glu Val Cys Asp Ala Arg Leu Gln Arg Cys Gln Val Ser Arg Glu
200 205 210
Pro Ser Tyr Ala Ala Phe Ser Thr Arg Gly Ala Phe His Leu Pro
215 220 225
Leu Gly Val Val Pro Phe Val Tyr Arg Lys Ile Tyr Glu Ala Ala
230 235 240
Lys Phe Arg Phe Gly Arg Arg Arg Arg Ala Val Leu Pro Leu Pro
245 250 255
Ala Thr Met Gln Val Lys Val Lys Glu Ala Pro Asp Glu Ala Glu
260 265 270
Val Val Phe Thr Ala His Cys Lys Ala Thr Val Ser Phe Gln Val
275 280 285
Ser Gly Asp Ser Trp Arg Glu Gln Lys Glu Arg Arg Ala Ala Met
290 295 300
Met Val Gly Ile Leu Ile Gly Val Phe Val Leu Cys Trp Ile Pro
305 310 315
Phe Phe Leu Thr Glu Leu Ile Ser Pro Leu Cys Ala Cys Ser Leu
320 325 330
Pro Pro Ile Trp Lys Ser Ile Phe Leu Trp Leu Gly Tyr Ser Asn
335 340 345
Ser Phe Phe Asn Pro Leu Ile Tyr Thr Ala Phe Asn Lys Asn Tyr
350 355 360
Asn Asn Ala Phe Lys Ser Leu Phe Thr Lys Gln Arg
365 370

<210> 9
<211> 330

<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474848CD1

<400> 9
Met Asp Pro Thr Thr Pro Ala Trp Gly Thr Glu Ser Thr Thr Val
1 5 10 15
Asn Gly Asn Asp Gln Ala Leu Leu Leu Leu Cys Gly Lys Glu Thr
20 25 30
Leu Ile Pro Val Phe Leu Ile Leu Phe Ile Ala Leu Val Gly Leu
35 40 45
Val Gly Asn Gly Phe Val Leu Trp Leu Leu Gly Phe Arg Met Arg
50 55 60
Arg Asn Ala Phe Ser Val Tyr Val Leu Ser Leu Ala Gly Ala Asp
65 70 75
Phe Leu Phe Leu Cys Phe Gln Ile Ile Asn Cys Leu Val Tyr Leu
80 85 90
Ser Asn Phe Phe Cys Ser Ile Ser Ile Asn Phe Pro Ser Phe Phe
95 100 105
Thr Thr Val Met Thr Cys Ala Tyr Leu Ala Gly Leu Ser Met Leu
110 115 120
Ser Thr Val Ser Thr Glu Arg Cys Leu Ser Val Leu Trp Pro Ile
125 130 135
Trp Tyr Arg Cys Arg Arg Pro Arg His Leu Ser Ala Val Val Cys
140 145 150
Val Leu Leu Trp Ala Leu Ser Leu Leu Leu Ser Ile Leu Glu Gly
155 160 165
Lys Phe Cys Gly Phe Leu Phe Ser Asp Gly Asp Ser Gly Trp Cys
170 175 180
Gln Thr Phe Asp Phe Ile Thr Ala Ala Trp Leu Ile Phe Leu Phe
185 190 195
Met Val Leu Cys Gly Ser Ser Leu Ala Leu Leu Val Arg Ile Leu
200 205 210
Cys Gly Ser Arg Gly Leu Pro Leu Thr Arg Leu Tyr Leu Thr Ile
215 220 225
Leu Leu Thr Val Leu Val Phe Leu Leu Cys Gly Leu Pro Phe Gly
230 235 240
Ile Gln Trp Phe Leu Ile Leu Trp Ile Trp Lys Asp Ser Asp Val
245 250 255
Leu Phe Cys His Ile His Pro Val Ser Val Val Leu Ser Ser Leu
260 265 270
Asn Ser Ser Ala Asn Pro Ile Ile Tyr Phe Phe Val Gly Ser Phe
275 280 285
Arg Lys Gln Trp Arg Leu Gln Gln Pro Ile Leu Lys Leu Ala Leu
290 295 300
Gln Arg Ala Leu Gln Asp Ile Ala Glu Val Asp His Ser Glu Gly
305 310 315
Cys Phe Arg Gln Gly Thr Pro Glu Met Ser Arg Ser Ser Leu Val
320 325 330

<210> 10
<211> 494
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7655614CD1

<400> 10

```
Met Glu Glu Pro Gln Pro Pro Arg Pro Pro Ala Ser Met Ala Leu
  1               5                  10                  15
Leu Gly Ser Gln His Ser Gly Ala Pro Ser Ala Ala Gly Pro Pro
             20                  25                  30
Gly Gly Thr Ser Ser Ala Ala Thr Ala Ala Val Leu Ser Phe Ser
         35                  40                  45
Thr Val Ala Thr Ala Ala Leu Gly Asn Leu Ser Asp Ala Ser Gly
     50                  55                  60
Gly Gly Thr Ala Ala Ala Pro Gly Gly Gly Gly Leu Gly Gly Ser
 65                  70                  75
Gly Ala Ala Arg Glu Ala Gly Ala Ala Val Arg Arg Pro Leu Gly
             80                  85                  90
Pro Glu Ala Ala Pro Leu Leu Ser His Gly Ala Ala Val Ala Ala
         95                 100                 105
Gln Ala Leu Val Leu Leu Leu Ile Phe Leu Leu Ser Ser Leu Gly
    110                 115                 120
Asn Cys Ala Val Met Gly Val Ile Val Lys His Arg Gln Leu Arg
    125                 130                 135
Thr Val Thr Asn Ala Phe Ile Leu Ser Leu Ser Leu Ser Asp Leu
    140                 145                 150
Leu Thr Ala Leu Leu Cys Leu Pro Ala Ala Phe Leu Asp Leu Phe
    155                 160                 165
Thr Pro Pro Gly Gly Ser Ala Pro Ala Ala Ala Ala Gly Pro Trp
    170                 175                 180
Arg Gly Phe Cys Ala Ala Ser Arg Phe Phe Ser Ser Cys Phe Gly
    185                 190                 195
Ile Val Ser Thr Leu Ser Val Ala Leu Ile Ser Leu Asp Arg Tyr
    200                 205                 210
Cys Ala Ile Val Arg Pro Pro Arg Glu Lys Ile Gly Arg Arg Arg
    215                 220                 225
Ala Leu Gln Leu Leu Ala Gly Ala Trp Leu Thr Ala Leu Gly Phe
    230                 235                 240
Ser Leu Pro Trp Glu Leu Leu Gly Ala Pro Arg Glu Leu Ala Ala
    245                 250                 255
Ala Gln Ser Phe His Gly Cys Leu Tyr Arg Thr Ser Pro Asp Pro
    260                 265                 270
Ala Gln Leu Gly Ala Ala Phe Ser Val Gly Leu Val Val Ala Cys
    275                 280                 285
Tyr Leu Leu Pro Phe Leu Leu Met Cys Phe Cys His Tyr His Ile
    290                 295                 300
Cys Lys Thr Val Arg Leu Ser Asp Val Arg Val Arg Pro Val Asn
    305                 310                 315
Thr Tyr Ala Arg Val Leu Arg Phe Phe Ser Glu Val Arg Thr Ala
    320                 325                 330
Thr Thr Val Leu Ile Met Ile Val Phe Val Ile Cys Cys Trp Gly
    335                 340                 345
Pro Tyr Cys Phe Leu Val Leu Leu Ala Ala Ala Arg Gln Ala Gln
    350                 355                 360
Thr Met Gln Ala Pro Ser Leu Leu Ser Val Val Ala Val Trp Leu
    365                 370                 375
Thr Trp Ala Asn Gly Ala Ile Asn Pro Val Ile Tyr Ala Ile Arg
    380                 385                 390
Asn Pro Asn Ile Ser Met Leu Leu Gly Arg Asn Arg Glu Glu Gly
    395                 400                 405
Tyr Arg Thr Arg Asn Val Asp Ala Phe Leu Pro Ser Gln Gly Pro
    410                 415                 420
Gly Leu Gln Ala Arg Ser Arg Ser Arg Leu Arg Asn Arg Tyr Ala
    425                 430                 435
Asn Arg Leu Gly Ala Cys Asn Arg Met Ser Ser Ser Asn Pro Ala
    440                 445                 450
Ser Gly Val Ala Gly Asp Val Ala Met Trp Ala Arg Lys Asn Pro
    455                 460                 465
```

```
Val Val Leu Phe Cys Arg Glu Gly Pro Pro Glu Pro Val Thr Ala
                470                 475                 480
Val Thr Lys Gln Pro Lys Ser Glu Ala Gly Asp Thr Ser Leu
                485                 490

<210> 11
<211> 532
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 6792419CD1

<400> 11
Met Asn Lys Ser Thr Cys Leu Met Ala Ala Glu Thr Pro Ser Lys
  1                 5                  10                  15
Arg Trp Arg Leu His Cys Leu Ala Phe Ser Gln Arg Phe Val Arg
                 20                  25                  30
Ala Gly Pro Ala Cys Ser Ser Arg Glu Ala Cys Ser Ser Pro Arg
                 35                  40                  45
Ala Gly Trp Asn Pro Ala Gly Phe Arg Leu Pro Gly Arg Trp Ser
                 50                  55                  60
Pro Phe Val Ala Leu His Leu Val Cys Gln Ile Arg Glu Ala Leu
                 65                  70                  75
Lys Leu Arg Ser Gly His Arg Thr Pro Ser Gly Ala Gly Ser Ser
                 80                  85                  90
Met Gln Pro Pro Pro Ser Leu Cys Gly Arg Ala Leu Val Ala Leu
                 95                 100                 105
Val Leu Ala Cys Gly Leu Ser Arg Ile Trp Gly Glu Glu Arg Gly
                110                 115                 120
Phe Pro Pro Asp Arg Ala Thr Pro Leu Leu Gln Thr Ala Glu Ile
                125                 130                 135
Met Thr Pro Pro Thr Lys Thr Leu Trp Pro Lys Gly Ser Asn Ala
                140                 145                 150
Ser Leu Ala Arg Ser Leu Ala Pro Ala Glu Val Pro Lys Gly Asp
                155                 160                 165
Arg Thr Ala Gly Ser Pro Pro Arg Thr Ile Ser Pro Pro Pro Cys
                170                 175                 180
Gln Gly Pro Ile Glu Ile Lys Glu Thr Phe Lys Tyr Ile Asn Thr
                185                 190                 195
Val Val Ser Cys Leu Val Phe Val Leu Gly Ile Ile Gly Asn Ser
                200                 205                 210
Thr Leu Leu Arg Ile Ile Tyr Lys Asn Lys Cys Met Arg Asn Gly
                215                 220                 225
Pro Asn Ile Leu Ile Ala Ser Leu Ala Leu Gly Asp Leu Leu His
                230                 235                 240
Ile Val Ile Asp Ile Pro Ile Asn Val Tyr Lys Leu Leu Ala Glu
                245                 250                 255
Asp Trp Pro Phe Gly Ala Glu Met Cys Lys Leu Val Pro Phe Ile
                260                 265                 270
Gln Lys Ala Ser Val Gly Ile Thr Val Leu Ser Leu Cys Ala Leu
                275                 280                 285
Ser Ile Asp Arg Tyr Arg Ala Val Ala Ser Trp Ser Arg Ile Lys
                290                 295                 300
Gly Ile Gly Val Pro Lys Trp Thr Ala Val Glu Ile Val Leu Ile
                305                 310                 315
Trp Val Val Ser Val Val Leu Ala Val Pro Glu Ala Ile Gly Phe
                320                 325                 330
Asp Ile Ile Thr Met Asp Tyr Lys Gly Ser Tyr Leu Arg Ile Cys
                335                 340                 345
Leu Leu His Pro Val Gln Lys Thr Ala Phe Met Gln Phe Tyr Lys
                350                 355                 360
```

```
Thr Ala Lys Asp Trp Trp Leu Phe Ser Phe Tyr Phe Cys Leu Pro
                365                 370                 375
Leu Ala Ile Thr Ala Phe Phe Tyr Thr Leu Met Thr Cys Glu Met
                380                 385                 390
Leu Arg Lys Lys Ser Gly Met Gln Ile Ala Leu Asn Asp His Leu
                395                 400                 405
Lys Gln Arg Arg Glu Val Ala Lys Thr Val Phe Cys Leu Val Leu
                410                 415                 420
Val Phe Ala Leu Cys Trp Leu Pro Leu His Leu Ser Arg Ile Leu
                425                 430                 435
Lys Leu Thr Leu Tyr Asn Gln Asn Asp Pro Asn Arg Cys Glu Leu
                440                 445                 450
Leu Ser Phe Leu Leu Val Leu Asp Tyr Ile Gly Ile Asn Met Ala
                455                 460                 465
Ser Leu Asn Ser Cys Ile Asn Pro Ile Ala Leu Tyr Leu Val Ser
                470                 475                 480
Lys Arg Phe Lys Asn Cys Phe Lys Ser Cys Leu Cys Cys Trp Cys
                485                 490                 495
Gln Ser Phe Glu Glu Lys Gln Ser Leu Glu Glu Lys Gln Ser Cys
                500                 505                 510
Leu Lys Phe Lys Ala Asn Asp His Gly Tyr Asp Asn Phe Arg Ser
                515                 520                 525
Ser Asn Lys Tyr Ser Ser Ser
                530
```

<210> 12
<211> 485
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474790CD1

<400> 12

```
Met Pro Ile Ser Leu Ala His Gly Ile Ile Arg Ser Thr Val Leu
  1                 5                  10                  15
Val Ile Phe Leu Ala Ala Ser Phe Val Gly Asn Ile Val Leu Ala
                 20                  25                  30
Leu Val Leu Gln Arg Lys Pro Gln Leu Leu Gln Val Thr Asn Arg
                 35                  40                  45
Phe Ile Phe Asn Leu Leu Val Thr Asp Leu Leu Gln Ile Ser Leu
                 50                  55                  60
Val Ala Pro Trp Val Val Ala Thr Ser Val Pro Leu Phe Trp Pro
                 65                  70                  75
Leu Asn Ser His Phe Cys Thr Ala Leu Val Ser Leu Thr His Leu
                 80                  85                  90
Phe Ala Phe Ala Ser Val Asn Thr Ile Val Val Val Ser Val Asp
                 95                 100                 105
Arg Tyr Leu Ser Ile Ile His Pro Leu Ser Tyr Pro Ser Lys Met
                110                 115                 120
Thr Gln Arg Arg Gly Tyr Leu Leu Leu Tyr Gly Thr Trp Ile Val
                125                 130                 135
Ala Ile Leu Gln Ser Thr Pro Pro Leu Tyr Gly Trp Gly Gln Ala
                140                 145                 150
Ala Phe Asp Glu Arg Asn Ala Leu Cys Ser Met Ile Trp Gly Ala
                155                 160                 165
Ser Pro Ser Tyr Thr Ile Leu Ser Val Val Ser Phe Ile Val Ile
                170                 175                 180
Pro Leu Ile Val Met Ile Ala Cys Tyr Ser Val Val Phe Cys Ala
                185                 190                 195
Ala Arg Arg Gln His Ala Leu Leu Tyr Asn Val Lys Arg His Ser
                200                 205                 210
```

```
Leu Glu Val Arg Val Lys Asp Cys Val Glu Asn Glu Asp Glu Glu
                215                 220                 225
Gly Ala Glu Lys Lys Glu Glu Phe Gln Asp Glu Ser Glu Phe Arg
                230                 235                 240
Arg Gln His Glu Gly Glu Val Lys Ala Lys Glu Gly Arg Met Glu
                245                 250                 255
Ala Lys Asp Gly Ser Leu Lys Ala Lys Glu Gly Ser Thr Gly Thr
                260                 265                 270
Ser Glu Ser Ser Val Glu Ala Arg Gly Ser Glu Glu Val Arg Glu
                275                 280                 285
Ser Ser Thr Val Ala Ser Asp Gly Ser Met Glu Gly Lys Glu Gly
                290                 295                 300
Ser Thr Lys Val Glu Glu Asn Ser Met Lys Ala Asp Lys Gly Arg
                305                 310                 315
Thr Glu Val Asn Gln Cys Ser Ile Asp Leu Gly Glu Asp Asp Met
                320                 325                 330
Glu Phe Gly Glu Asp Asp Ile Asn Phe Ser Glu Asp Asp Val Glu
                335                 340                 345
Ala Val Asn Ile Pro Glu Ser Leu Pro Pro Ser Arg Arg Asn Ser
                350                 355                 360
Asn Ser Asn Pro Pro Leu Pro Arg Cys Tyr Gln Cys Lys Ala Ala
                365                 370                 375
Lys Val Ile Phe Ile Ile Ile Phe Ser Tyr Val Leu Ser Leu Gly
                380                 385                 390
Pro Tyr Cys Phe Leu Ala Val Leu Ala Val Trp Val Asp Val Glu
                395                 400                 405
Thr Gln Val Pro Gln Trp Val Ile Thr Ile Ile Ile Trp Leu Phe
                410                 415                 420
Phe Leu Gln Cys Cys Ile His Pro Tyr Val Tyr Gly Tyr Met His
                425                 430                 435
Lys Thr Ile Lys Lys Glu Ile Gln Asp Met Leu Lys Lys Phe Phe
                440                 445                 450
Cys Lys Glu Lys Pro Pro Lys Glu Asp Ser His Pro Asp Leu Pro
                455                 460                 465
Gly Thr Glu Gly Gly Thr Glu Gly Lys Ile Val Pro Ser Tyr Asp
                470                 475                 480
Ser Ala Thr Phe Pro
                485
```

<210> 13
<211> 255
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474816CD1

<400> 13

```
Met Pro Phe Ile Ser Lys Leu Val Leu Ala Ser Gln Pro Thr Leu
  1               5                  10                  15
Phe Ser Phe Phe Ser Ala Ser Ser Pro Phe Leu Leu Phe Leu Asp
                 20                  25                  30
Leu Arg Pro Glu Arg Thr Tyr Leu Pro Val Cys His Val Ala Leu
                 35                  40                  45
Ile His Met Val Val Leu Leu Thr Met Val Phe Leu Ser Pro Gln
                 50                  55                  60
Leu Phe Glu Ser Leu Asn Phe Gln Asn Asp Phe Lys Tyr Glu Ala
                 65                  70                  75
Ser Phe Tyr Leu Arg Arg Val Ile Arg Asp Leu Ser Ile Cys Thr
                 80                  85                  90
Thr Cys Leu Leu Gly Met Leu Gln Val Val Asn Ile Ser Pro Ser
                 95                 100                 105
```

```
Ile Ser Trp Leu Val Arg Phe Lys Trp Lys Ser Thr Ile Phe Thr
                110                 115                 120
Phe His Leu Phe Ser Trp Ser Leu Ser Phe Pro Val Ser Ser Ser
                125                 130                 135
Leu Ile Phe Tyr Thr Val Ala Ser Ser Asn Val Thr Gln Ile Asn
                140                 145                 150
Leu His Val Ser Lys Tyr Cys Ser Leu Phe Pro Ile Asn Ser Ile
                155                 160                 165
Ile Arg Gly Leu Phe Phe Thr Leu Ser Leu Phe Arg Asp Val Phe
                170                 175                 180
Leu Lys Gln Ile Met Leu Phe Ser Ser Val Tyr Met Met Thr Leu
                185                 190                 195
Ile Gln Glu Leu Gln Glu Ile Leu Val Pro Ser Gln Pro Gln Pro
                200                 205                 210
Leu Pro Lys Asp Leu Cys Arg Gly Lys Ser His Gln His Ile Leu
                215                 220                 225
Leu Pro Val Ser Phe Ser Val Gly Met Tyr Lys Met Asp Phe Ile
                230                 235                 240
Ile Ser Thr Ser Ser Thr Leu Pro Trp Ala Tyr Asp Arg Gly Val
                245                 250                 255
```

<210> 14
<211> 881
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7476172CD1

<400> 14

```
Met Ser Ile Glu Glu Leu Cys Ser Asp Phe Lys Lys Tyr Leu Phe
  1               5                  10                  15
Pro Asn Ser Phe Glu Ile Ser Val Phe Leu Gln Thr Leu Ala Met
                 20                  25                  30
Ile His Ser Ile Glu Met Ile Asn Asn Ser Thr Leu Leu Pro Gly
                 35                  40                  45
Val Lys Leu Gly Tyr Glu Ile Tyr Asp Thr Cys Thr Glu Val Thr
                 50                  55                  60
Val Ala Met Ala Ala Thr Leu Arg Phe Leu Ser Lys Phe Asn Cys
                 65                  70                  75
Ser Arg Glu Thr Val Glu Phe Lys Cys Asp Tyr Ser Ser Tyr Met
                 80                  85                  90
Pro Arg Val Lys Ala Val Ile Gly Ser Gly Tyr Ser Glu Ile Thr
                 95                 100                 105
Met Ala Val Ser Arg Met Leu Asn Leu Gln Leu Met Pro Gln Val
                110                 115                 120
Gly Tyr Glu Ser Thr Ala Glu Ile Leu Ser Asp Lys Ile Arg Phe
                125                 130                 135
Pro Ser Phe Leu Arg Thr Val Pro Ser Asp Phe His Gln Ile Lys
                140                 145                 150
Ala Met Ala His Leu Ile Gln Lys Ser Gly Trp Asn Trp Ile Gly
                155                 160                 165
Ile Ile Thr Thr Asp Asp Asp Tyr Gly Arg Leu Ala Leu Asn Thr
                170                 175                 180
Phe Ile Ile Gln Ala Glu Ala Asn Asn Val Cys Ile Ala Phe Lys
                185                 190                 195
Glu Val Leu Pro Ala Phe Leu Ser Asp Asn Thr Ile Glu Val Arg
                200                 205                 210
Ile Asn Arg Thr Leu Lys Lys Ile Ile Leu Glu Ala Gln Val Asn
                215                 220                 225
Val Ile Val Val Phe Leu Arg Gln Phe His Val Phe Asp Leu Phe
```

```
                230                 235                 240
Asn Lys Ala Ile Glu Met Asn Ile Asn Lys Met Trp Ile Ala Ser
                245                 250                 255
Asp Asn Trp Ser Thr Ala Thr Lys Ile Thr Thr Ile Pro Asn Val
                260                 265                 270
Lys Lys Ile Gly Lys Val Val Gly Phe Ala Phe Arg Arg Gly Asn
                275                 280                 285
Ile Ser Ser Phe His Ser Phe Leu Gln Asn Leu His Leu Leu Pro
                290                 295                 300
Ser Asp Ser His Lys Leu Leu His Glu Tyr Ala Met His Leu Ser
                305                 310                 315
Ala Cys Ala Tyr Val Lys Asp Thr Asp Leu Ser Gln Cys Ile Phe
                320                 325                 330
Asn His Ser Gln Arg Thr Leu Ala Tyr Lys Ala Asn Lys Ala Ile
                335                 340                 345
Glu Arg Asn Phe Val Met Arg Asn Asp Phe Leu Trp Asp Tyr Ala
                350                 355                 360
Glu Pro Gly Leu Ile His Ser Ile Gln Leu Ala Val Phe Ala Leu
                365                 370                 375
Gly Tyr Ala Ile Arg Asp Leu Cys Gln Ala Arg Asp Cys Gln Asn
                380                 385                 390
Pro Asn Ala Phe Gln Pro Trp Glu Leu Leu Gly Val Leu Lys Asn
                395                 400                 405
Val Thr Phe Thr Asp Gly Trp Asn Ser Phe His Phe Asp Ala His
                410                 415                 420
Gly Asp Leu Asn Thr Gly Tyr Asp Val Val Leu Trp Lys Glu Ile
                425                 430                 435
Asn Gly His Met Thr Val Thr Lys Met Ala Glu Tyr Asp Leu Gln
                440                 445                 450
Asn Asp Val Phe Ile Ile Pro Asp Gln Glu Thr Lys Asn Glu Phe
                455                 460                 465
Arg Asn Leu Lys Leu Thr Leu Phe Ser Val Leu Thr Lys Leu Lys
                470                 475                 480
His Gln Lys Arg Ile Pro Val Ala Thr Val Thr Ser Val Pro Val
                485                 490                 495
Pro Leu Pro Ser Ile Trp His Tyr Arg Gln Thr Val Cys Ala Pro
                500                 505                 510
Ser Gln Asp Met Pro His Cys Leu Leu Cys Asn Asn Lys Thr His
                515                 520                 525
Trp Ala Pro Val Arg Ser Thr Met Cys Phe Glu Lys Glu Val Glu
                530                 535                 540
Tyr Leu Asn Trp Asn Asp Ser Leu Ala Ile Leu Leu Leu Ile Leu
                545                 550                 555
Ser Leu Leu Gly Ile Ile Phe Val Leu Val Val Gly Ile Ile Phe
                560                 565                 570
Thr Arg Asn Leu Asn Thr Pro Val Val Lys Ser Ser Gly Gly Leu
                575                 580                 585
Arg Val Cys Tyr Val Ile Leu Leu Cys His Phe Leu Asn Phe Ala
                590                 595                 600
Ser Thr Ser Phe Phe Ile Gly Glu Pro Gln Asp Phe Thr Cys Lys
                605                 610                 615
Thr Arg Gln Thr Met Phe Gly Val Ser Phe Thr Leu Cys Ile Ser
                620                 625                 630
Cys Ile Leu Thr Lys Ser Leu Lys Ile Leu Leu Ala Phe Ser Phe
                635                 640                 645
Asp Pro Lys Leu Gln Lys Phe Leu Lys Cys Leu Tyr Arg Pro Ile
                650                 655                 660
Leu Ile Ile Phe Thr Cys Thr Gly Ile Gln Val Val Ile Cys Thr
                665                 670                 675
Leu Trp Leu Ile Phe Ala Ala Pro Thr Val Glu Val Asn Val Ser
                680                 685                 690
Leu Pro Arg Val Ile Ile Leu Glu Cys Glu Glu Gly Ser Ile Leu
                695                 700                 705
```

```
Ala Phe Gly Thr Met Leu Gly Tyr Ile Ala Ile Leu Ala Phe Ile
                710                 715                 720
Cys Phe Ile Phe Ala Phe Lys Gly Lys Tyr Glu Asn Tyr Asn Glu
                725                 730                 735
Ala Lys Phe Ile Thr Phe Gly Met Leu Ile Tyr Phe Ile Ala Trp
                740                 745                 750
Ile Thr Phe Ile Pro Ile Tyr Ala Thr Thr Phe Gly Lys Tyr Val
                755                 760                 765
Pro Ala Val Glu Ile Ile Val Ile Leu Ile Ser Asn Tyr Gly Ile
                770                 775                 780
Leu Tyr Cys Thr Phe Ile Pro Lys Cys Tyr Val Ile Ile Cys Lys
                785                 790                 795
Gln Glu Ile Asn Thr Lys Ser Ala Phe Leu Lys Met Ile Tyr Ser
                800                 805                 810
Tyr Ser Ser His Ser Val Ser Ser Ile Ala Leu Ser Pro Ala Ser
                815                 820                 825
Leu Asp Ser Met Ser Gly Asn Val Thr Met Thr Asn Pro Ser Ser
                830                 835                 840
Ser Gly Lys Ser Ala Thr Trp Gln Lys Ser Lys Asp Leu Gln Ala
                845                 850                 855
Gln Ala Phe Ala His Ile Cys Arg Glu Asn Ala Thr Ser Val Ser
                860                 865                 870
Lys Thr Leu Pro Arg Lys Arg Met Ser Ser Ile
                875                 880
```

<210> 15
<211> 309
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472141CD1

<400> 15

```
Met Leu Leu Asn His Thr Leu Ile Thr Glu Phe Leu Leu Leu Gly
  1                 5                  10                  15
Val Thr Asp Ile Gln Glu Leu Asn Pro Ile Leu Phe Val Met Val
                 20                  25                  30
Leu Ala Met Tyr Phe Ile Asn Val Phe Gly Asn Gly Ala Ile Met
                 35                  40                  45
Met Ile Val Ile Leu Asp Pro Arg Leu Tyr Ser Pro Met Tyr Phe
                 50                  55                  60
Phe Leu Gly Asn Leu Ala Cys Leu Asp Ile Cys Phe Ser Thr Val
                 65                  70                  75
Thr Val Pro Lys Met Leu Glu Asn Phe Phe Ser Thr Ser Lys Ala
                 80                  85                  90
Ile Ser Phe Leu Gly Cys Ile Thr Gln Leu His Phe Phe His Phe
                 95                 100                 105
Leu Gly Ser Thr Glu Ala Leu Leu Leu Thr Val Met Ala Phe Asp
                110                 115                 120
Arg Phe Val Ala Ile Cys Arg Pro Leu His Tyr Pro Val Ile Met
                125                 130                 135
Asn Arg Gln Leu Cys Ile His Met Thr Val Thr Ile Trp Thr Ile
                140                 145                 150
Gly Phe Phe His Ala Leu Leu His Ser Val Met Thr Ser Arg Leu
                155                 160                 165
Ser Phe Cys Gly Ser Asn His Ile His His Phe Phe Cys Asp Val
                170                 175                 180
Lys Pro Leu Leu Asp Leu Ala Cys Gly Asn Thr Glu Leu Asn Leu
                185                 190                 195
Trp Leu Leu Asn Thr Val Thr Gly Thr Ile Ala Leu Thr Ser Phe
                200                 205                 210
```

```
Tyr Leu Ile Phe Leu Ser Tyr Phe Tyr Ile Ile Thr Asn Leu Leu
                215                 220                 225
Leu Lys Thr Arg Ser Cys Ser Met Leu His Lys Ala Leu Ser Thr
                230                 235                 240
Cys Ala Ser His Phe Met Val Val Val Leu Phe Tyr Ala Pro Val
                245                 250                 255
Leu Phe Thr Tyr Ile Arg Pro Ala Ser Gly Ser Ser Leu Asp Gln
                260                 265                 270
Asp Thr Ile Ile Ala Ile Met Tyr Ser Val Val Thr Pro Ala Leu
                275                 280                 285
Asn Pro Leu Met Tyr Thr Leu Arg Asn Lys Glu Val Arg Ser Ala
                290                 295                 300
Leu Asn Arg Lys Val Arg Ser Ser Leu
                305
```

<210> 16
<211> 224
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472137CD1

<400> 16

```
Met Arg Asn Phe Ser Val Val Ser Glu Phe Ile Leu Leu Gly Ile
  1               5                  10                  15
Pro His Thr Glu Gly Leu Glu Thr Ile Leu Leu Val Leu Phe Leu
                20                  25                  30
Ser Phe Tyr Ile Phe Thr Leu Met Gly Asn Leu Leu Ile Leu Leu
                35                  40                  45
Ala Ile Val Ser Ser Ala Arg Leu His Thr Pro Met Tyr Phe Phe
                50                  55                  60
Leu Cys Lys Leu Ser Val Phe Asp Leu Phe Phe Pro Ser Val Ser
                65                  70                  75
Ser Pro Lys Met Leu Cys Tyr Leu Ser Gly Asn Ser Arg Ala Ile
                80                  85                  90
Ser Tyr Ala Gly Cys Ala Ser Gln Leu Phe Phe Tyr His Phe Leu
                95                  100                 105
Gly Cys Thr Glu Cys Phe Leu Tyr Thr Val Met Ala Tyr Asp Arg
                110                 115                 120
Phe Val Ala Ile Cys His Pro Leu Arg Tyr Thr Ile Ile Met Ser
                125                 130                 135
His Arg Ala Cys Ile Ile Leu Ala Met Gly Thr Ser Phe Phe Gly
                140                 145                 150
Cys Ile Gln Ala Thr Phe Leu Thr Thr Leu Thr Phe Gln Leu Pro
                155                 160                 165
Tyr Cys Val Pro Asn Glu Val Asp Tyr Tyr Phe Cys Asp Ile Pro
                170                 175                 180
Val Met Leu Lys Leu Ala Cys Ala Asp Thr Ser Ala Leu Glu Met
                185                 190                 195
Val Gly Phe Ile Ser Val Gly Leu Met Pro Leu Ser Cys Phe Leu
                200                 205                 210
Leu Ile Leu Thr Ser Tyr Ser Gly Ile Val Phe Ser Ile Leu
                215                 220
```

<210> 17
<211> 326
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature

<223> Incyte ID No: 7477934CD1

<400> 17
Met Gly His Gln Asn His Thr Phe Ser Ser Asp Phe Ile Leu Leu
1 5 10 15
Gly Leu Phe Ser Ser Asn Lys Cys Gly Leu Leu Leu Arg Gln Phe
20 25 30
Val Ile Phe Ile Met Ser Val Thr Glu Asn Thr Leu Met Ile Leu
35 40 45
Leu Ile Arg Ser Asp Ser Arg Leu His Thr Pro Met Tyr Phe Leu
50 55 60
Leu Ser His Leu Ser Leu Met Asp Ile Leu His Val Ser Asn Ile
65 70 75
Val Pro Lys Met Val Thr Asn Phe Leu Ser Gly Ser Arg Thr Ile
80 85 90
Ser Phe Ala Gly Cys Gly Phe Gln Val Phe Leu Ser Leu Thr Leu
95 100 105
Leu Gly Gly Glu Cys Leu Leu Leu Ala Ala Met Ser Cys Asp Arg
110 115 120
Tyr Val Ala Ile Cys His Pro Leu Arg Tyr Pro Ile Leu Met Lys
125 130 135
Glu Tyr Ala Ser Ala Leu Met Ala Gly Gly Ser Trp Leu Ile Gly
140 145 150
Val Phe Asn Ser Thr Val His Thr Ala Tyr Ala Leu Gln Phe Pro
155 160 165
Phe Cys Gly Ser Arg Ala Ile Asp His Phe Phe Cys Glu Val Pro
170 175 180
Ala Met Leu Lys Leu Ser Cys Ala Asp Thr Thr Arg Tyr Glu Arg
185 190 195
Gly Val Cys Val Ser Ala Val Ile Phe Leu Leu Ile Pro Phe Ser
200 205 210
Leu Ile Ser Ala Ser Tyr Gly Gln Ile Ile Leu Thr Val Leu Gln
215 220 225
Met Lys Ser Ser Glu Ala Arg Lys Lys Ser Phe Ser Thr Cys Ser
230 235 240
Phe His Met Ile Val Val Thr Met Tyr Tyr Gly Pro Phe Ile Phe
245 250 255
Thr Tyr Met Arg Pro Lys Ser Tyr His Thr Pro Gly Gln Asp Lys
260 265 270
Phe Leu Ala Ile Phe Tyr Thr Ile Leu Thr Pro Thr Leu Asn Pro
275 280 285
Phe Ile Tyr Ser Phe Arg Asn Lys Asp Val Leu Ala Val Met Lys
290 295 300
Asn Met Leu Lys Ser Asn Phe Leu His Lys Lys Met Asn Arg Lys
305 310 315
Ile Pro Glu Cys Val Phe Cys Leu Phe Leu Cys
320 325

<210> 18
<211> 2374
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1714538CB1

<400> 18
gtcagtcagt ccactggctc ccgcgccgcg tctgtgtccg tcgctcggag ggtggaagcc 60
ggggtctcgc gggccgcggg ccgcatgact cctctctgcc tcaattgctc tgtcctccct 120
ggagacctgt acccaggggg tgcaaggaac cccatggctt gcaatggcag tgcggccagg 180
gggcactttg accctgagga cttgaacctg actgacgagg cactgagact caagtacctg 240
gggccccagc agacagagct gttcatgccc atctgtgcca catacctgct gatcttcgtg 300

gtgggcgctg tgggcaatgg gctgacctgt ctggtcatcc tgcgccacaa ggccatgcgc 360
acgcctacca actactacct cttcagcctg gccgtgtcgg acctgctggt gctgctggtg 420
ggcctgcccc tggagctcta tgagatgtgg cacaactacc ccttcctgct gggcgttggt 480
ggctgctatt tccgcacgct actgtttgag atggtctgcc tggcctcagt gctcaacgtc 540
actgccctga gcgtggaacg ctatgtggcc gtggtgcacc cactccaggc caggtccatg 600
gtgacgcggg cccatgtgcg ccgagtgctt ggggccgtct ggggtcttgc catgctctgc 660
tccctgccca acaccagcct gcacggcatc cggcagctgc acgtgccctg ccggggccca 720
gtgccagact cagctgtttg catgctggtc cgcccacggg ccctctacaa catggtagtg 780
cagaccaccg cgctgctctt cttctgcctg cccatggcca tcatgagcgt gctctgcctg 840
ctcgttgggc tgcgactgcg gcgggagagg ctgctgctca tgcaggaggc caagggcagg 900
ggctctgcag cagccaggtc cagatacacc tgcaggctcc agcagcacga tcggggccgg 960
ggacaagtga ccaagatgct gtttgtcctg gtcgtggtgt ttggcatctg ctgggccccg 1020
ttccacgccg accgcgtcat gtggagcgtc gtgtcacagt ggacagatgg cctgcacctg 1080
gccttccagc acgtgcacgt catctccggc atcttcttct acctgggctc ggcggccaac 1140
cccgtgctct atagcctcat gtccagccgc ttccgagaga ccttccagga ggccctgtgc 1200
ctcggggcct gctgccatcg cctcagaccc cgccacagct cccacagcct cagcaggatg 1260
accacaggca gcaccctgtg tgatgtgggc tccctgggca gctgggtcca ccccctggct 1320
gggaacgatg gcccagaggc gcagcaagag accgatccat cctgagtgga gccttaaagt 1380
ggcttcacct ggaggggcca gagggtcacc tggagctggg gagacacatc tgccttcctc 1440
tgcagggatg ccttcacgta ctgtccctag ttcagcctag aaattctgac cagcacctca 1500
gtttccctca gagggaaaca gcaggaggag ggatccctga ctgctgagga ctcacactga 1560
ccagacgcca caccttgtgc ttcttatctg tccactgcca ctcccccagt tcaaatcctt 1620
accctgcaga aatatcacag ttagctgggg ctcagcagtc ctccctctgg ggactccctg 1680
ccaccactgc cagtttctga aacggtccca ctgggtcctc actgtccttc ccagttcctg 1740
ttcaggttct ggcaggggcc cagggatcca ggggacctgg ttccaatctc agccctgctg 1800
tcaccacctt gtcatgcacc atcaagcata tcagtctacc tttctttttt tctgagacag 1860
agtctcactc tgtcgcccag gctggagtgc agtggcgcga ttttgactcg ctgcaacctc 1920
cgcctccggg gttcaggcga ttctcctgcc tcagcctccc gagtagctgg gactacaggt 1980
gagccccagc atgcccagct aatttttttt agtttttagt agagacgggg tttcaccatg 2040
ttggccaggc tggtctcgaa ctcttgacct caggtgatcc gccgacctcg gcctcccaaa 2100
gtcctcggat tacaggcatg agccaccaca cccggccaat cagtccacct ttctaggcct 2160
tggttccttg cctgaaaaat gaaagaggcg ctggctttcc acagtgtcat gctttggcac 2220
tttagctatg gttttctttc tgtgtgtgtg taagccactg cttataataa aaccaacaat 2280
accctcagac tgaaagggcg gaagttatta tctgcatctt tatcaacccc aagccccact 2340
tcctccctga cctccccatg ccctccccag cctc 2374

<210> 19
<211> 813
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3406743CB1

<400> 19
ctcttcggtg cctcttcttc ctccgggaca aggatggagg atctctttag cccctcaatt 60
ctgccgccgg cgcccaacat ttccgtgccc atcttgctgg gctggggtct caacctgacc 120
ttggggcaag gagcccctgc ctctgggccg cccagccgcc gcgtccgcct ggtgttcctg 180
ggggtcatcc tggtggtggc ggtggcaggc aacaccacag tgctgtgccg cctgtgcggc 240
ggcggcgggc cctgggcggg ccccaagcgt cgcaagatgg acttcctgct ggtgcagctg 300
gccctggcgg acctgtacgc gtgcgggggc acggcgctgt cacagctggc ctgggaactg 360
ctgggcgagc cccgcgcggc cacgggggac ctggcgtgcc gcttcctgca gctgctgcag 420
gcatccgggc ggggcgcctc ggcccacctc gtggtgctca tcgccctcga gcgccggcgc 480
gcgccaggcg cgccactctc cgcccgagcc tggccgggga tgcgtcgctg ccactggatc 540
ttcgcgctcc tgcagcgctg gcacgtgcag gtgtacgcgt tctatgaggc cgtcgcgggc 600
ttcgtcgcgc ctgttaagat catgggtgtc gcttgtggcc acctactctc cgtctggtgg 660
cggcaccggc tgaaggcccc agcgggtgca gcggcctggt cggcgagccc aggtggagcc 720
cgtgcgccca gcgcgatgcc ccgcgccaag gtgcagagcc tgaagatgag ccagctgctg 780
gggctgctgt tcgtgggctg cgagctgccc tag 813

<210> 20
<211> 1542

<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3485895CB1

<400> 20
tgaataaatt attcctgggc ttttgaatta ttaatcttgg ctgcaggata tgcaaatagg 60
atatgcaaat aggacacttg gcacaacact gggtcagaag ctatatccag ctgctggcag 120
agttcctgtc aagggatcaa gtcttccaac agaatggtta tggtttaact cagcagaatt 180
tgttgaacaa ctacgacatg ctggggatca tggcatggaa tgcaacttgc aaaaactggc 240
tggcagcaga ggctgccctg gaaaagtact acctttccat tttttatggg attgagttcg 300
ttgtgggagt ccttggaaat accattgttg tttacggcta catcttctct ctgaagaact 360
ggaacagcag taatatttat ctctttaacc tctctgtctc tgacttagct tttctgtgca 420
ccctccccat gctgataagg agttatgcca atggaaactg gatatatgga gacgtgctct 480
gcataagcaa ccgatatgtg cttcatgcca acctctatac cagcattctc tttctcactt 540
ttatcagcat agatcgatac ttgataatta agtatccttt ccgagaacac cttctgcaaa 600
agaaagagtt tgctatttta atctccttgg ccatttgggt tttagtaacc ttagagttac 660
tacccatact tccccttata aatcctgtta taactgacaa tggcaccacc tgtaatgatt 720
ttgcaagttc tggagacccc aactacaacc tcatttacag catgtgtcta acactgttgg 780
ggttccttat tcctcttttt gtgatgtgtt tcttttatta caagattgct ctcttcctaa 840
agcagaggaa taggcaggtt gctactgctc tgccccttga aaagcctctc aacttggtca 900
tcatggcagt ggtaatcttc tctgtgcttt ttacacccta tcacgtcatg cggaatgtga 960
ggatcgcttc acgcctgggg agttggaagc agtatcagtg cactcaggtc gtcatcaact 1020
ccttttacat tgtgacacgg cctttggcct ttctgaacag tgtcatcaac cctgtcttct 1080
attttctttt gggagatcac ttcagggaca tgctgatgaa tcaactgaga cacaacttca 1140
aatcccttac atcctttagc agatgggctc atgaactcct actttcattc agagaaaagt 1200
gaggggcttg tgaaacagat tgttctacag atgaatctgt aagccagtta cagtttgcct 1260
taactcatag acatcaatca gagagtgtca cagatttaac cttgatctaa agacaagttg 1320
tacccagagt atgtgaaaag aatgggacga caagaatgta ctggtttctt cctctaagaa 1380
ttgaaaggag ttgaactgcc ttatgtttgg gcatgtaact ccaaaatact aggtagtata 1440
aggctttctc aatcagtgca aaaatggaag atatataaag caacaagttg tctgcatttg 1500
atcactggtc agattgtaaa aaaaaaaaaa aagggcggcc gc 1542

<210> 21
<211> 1191
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7476102CB1

<400> 21
atgggggatg agctggcacc ttgccctgtg ggcactacag cttggccggc cctgatccag 60
ctcatcagca agacaccctg catgccccaa gcagccagca acacttcctt gggcctgggg 120
gacctcaggg tgcccagctc catgctgtac tggcttttcc ttccctcaag cctgctggct 180
gcagccacac tggctgtcag ccccctgctg ctggtgacca tcctgcggaa ccaacggctg 240
cgacaggagc cccactacct gctcccggct aacatcctgc tctcagacct ggcctacatt 300
ctcctccaca tgctcatctc ctccagcagc ctgggtggct gggagctggg ccgcatggcc 360
tgtggcattc tcactgatgc tgtcttcgcc gcctgcacca gcaccatcct gtccttcacc 420
gccattgtgc tgcacaccta cctggcagtc atccatccac tgcgctacct ctccttcatg 480
tcccatgggg ctgcctggaa ggcagtggcc ctcatctggc tggtggcctg ctgcttcccc 540
acattcctta tttggctcag caagtggcag gatgcccagc tggaggagca aggagcttca 600
tacatcctac caccaagcat gggcacccag ccgggatgtg gcctcctggt cattgttacc 660
tacacctcca ttctgtgcgt tctgttcctc tgcacagctc tcattgccaa ctgtttctgg 720
aggatctatg cagaggccaa gacttcaggc atctgggggc agggctattc ccgggccagg 780
ggcaccctgc tgatccactc agtgctgatc acattgtacg tgagcacagg ggtggtgttc 840
tccctggaca tggtgctgac caggtaccac cacattgact ctgggactca cacatggctc 900
ctggcagcta acagtgaggt actcatgatg cttccccgtg ccatgctcac atacctgtac 960
ctgctccgct accggcagct gttgggcatg gtccggggcc acctcccatc caggaggcac 1020
caggccatct ttaccatttc ctgctgctgg gaaccactat tctacttttc tctgattttg 1080

accactctag gagtggatat tattccattg tgtgtagaga ccacattttg tttatccatt 1140
catctgtcaa tggaccgttt gggttgcacc acctttggct attgtgaata a 1191

<210> 22
<211> 3360
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2432942CB1

<400> 22
cccacgcgtc cggcagctga gacggcagcg gcagcttctc agggccggag ccagttcttg 60
gaggagactc tgcgcagggc atggatcact gtggtgccct tttcctgtgc ctgtgccttc 120
tgactttgca gaatgcaaca acagagacat gggaagaact cctgagctac atggagaata 180
tgcaggtgtc caggggccgg agctcagttt tttcctctcg tcaactccac cagctggagc 240
agatgctact gaacaccagc ttcccaggct acaacctgac cttgcagaca cccaccatcc 300
agtctctggc cttcaagctg agctgtgact tctctggcct ctcgctgacc agtgccactc 360
tgaagcgggt gccccaggca ggaggtcagc atgcccgggg tcagcacgcc atgcagttcc 420
ccgccgagct gacccgggac gcctgcaaga cccgccccag ggagctgcgg ctcatctgta 480
tctacttctc caacacccac tttttcaagg atgaaaacaa ctcatctctg ctgaataact 540
acgtcctggg ggcccagctg agtcatgggc acgtgaacaa cctcagggat cctgtgaaca 600
tcagcttctg gcacaaccaa agcctggaag gctacaccct gacctgtgtc ttctggaagg 660
agggagccag gaaacagccc tgggggggct ggagccctga gggctgtcgt acagagcagc 720
cctcccactc tcaggtgctc tgccgctgca accacctcac ctactttgct gttctcatgc 780
aactctcccc agccctggtc cctgcagagt tgctggcacc tcttacgtac atctccctcg 840
tgggctgcag catctccatc gtggcctcgc tgatcacagt cctgctgcac ttccatttca 900
ggaagcagag tgactcctta acacgcatcc acatgaacct gcatgcctcc gtgctgctcc 960
tgaacatcgc cttcctgctg agccccgcat tcgcaatgtc tcctgtgccc gggtcagcat 1020
gcacggctct ggccgctgcc ctgcactacg cgctgctcag ctgcctcacc tggatggcca 1080
tcgagggctt caacctctac ctcctcctcg ggcgtgtcta caacatctac atccgcagat 1140
atgtgttcaa gcttggtgtg ctaggctggg gggccccagc cctcctggtg ctgctttccc 1200
tctctgtcaa gagctcggta tacggaccct gcacaatccc cgtcttcgac agctgggaga 1260
atggcacagg cttccagaac atgtccatat gctgggtgcg gagccccgtg gtgcacagtg 1320
tcctggtcat gggctacggc ggcctcacgt ccctcttcaa cctggtggtg ctggcctggg 1380
cgctgtggac cctgcgcagg ctgcgggagc gggcggatgc accaagtgtc agggcctgcc 1440
atgacactgt cactgtgctg ggcctcaccg tgctgctggg aaccacctgg gccttggcct 1500
tcttttcttt tggcgtcttc ctgctgcccc agctgttcct cttcaccatc ttaaactcgc 1560
tgtacggttt cttccttttc ctgtggttct gctcccagcg gtgccgctca gaagcagagg 1620
ccaaggcaca gatagaggcc ttcagctcct cccaaacaac acagtagtcc gggcctcctg 1680
gcctggaatc ctcagcctct ctggccgcca gtagcctgag gctacggctc ctgctagaga 1740
gggtggcagg cctgctgctg gaccccagag gccactgtga ccgccaaggg gccttttcca 1800
cttccacggc ctctccaggc actgagggga aggcattgct ctacctctcc ctgacatttt 1860
gctccggggc agatccaacc ttacctgggg cagcaaactt tgtcctggta cctgggccca 1920
gctcgccagg gatgtgggca gagcaccagc ctgggcatca ggaagccaag tttcaaggac 1980
tgtctttgag tctgtctgta tgaccttggg cctgccactt ctcacagacc ctaggtatcc 2040
acagctgtga catgggggca agcagctttg tttcagccta acccaggagc ttagtaaaaa 2100
ttgcataaga ccaggggggaa gagtgtcagc gtggggtggg aattcccgcg gcctccacct 2160
gcttgctagg ggcaggatct cattcaggct gccctggaag cacctgcttg gccctgccac 2220
cttcctccag gggagggcca gatggcatcc tggcttgggg cgggtgggac ctacccaggc 2280
tctgagactt tactggccta tgcctgaggc ctcttttcct ttaactccct aaattatgat 2340
gactccaagt ccaagcccac ccttcccaaa gattgggagg ttccgccgtt cccagaggct 2400
cctcctgcgg tgctcccaag acttccatag accatctgga ccagtagccc atcccgcagt 2460
tttcttgggg gcagaggaaa acgcttcttt ctcctccagc tgaatcagct ggatcccagt 2520
gtcctggctg tttggtgatt gggcaagatt gaatttgccc aggtaggcgt gagagtgtgg 2580
gttttaaatt cgaagctcag gccatagttt cagagaatca cccttacccc agaccttcat 2640
gagacagtgc tcatgaagcc agtgcgtttc ccagaacgaa cactaggcgg caccgttggt 2700
ccacactcag aggcccttgg cgccaagact gcatctagaa tcgctcaaac acctgtttgc 2760
agaccccatg caccagctgg aggggccgta actgcaggac tgcgcctact gagtgaccca 2820
tttcctccag gaggaaaggc aagacacgct tacacggcca tttgtctctt ttcccaatgc 2880
ggcggtgcac tttcgctctt gggggctgca ccccagacat agctggcacc agagcagggt 2940
gctcaggtgg tgggtgctca gggccctgcc ccaggccact gggccgtttt gatgaccttg 3000

aaggtcacag gcagaaaata ggagcaggat ttcccctggg gaaaagttct cctgggacat 3060
cttctgctct tctgtacatt tctagatgca aataactcct tcaccaggca gtgagtggcg 3120
taggctctgg agccaggctg cctgggctcc aatgccagct ctgccacttg ctagctgtga 3180
gactgtggac aaaccactca gcctctgtgt gcctcagttt tcctatttgt aaaatagagg 3240
ccatagtggt acctattttg aagactaagt aaaagaattc aaataaagag acttggcaca 3300
gagtaagtgc tcagtaaaaa aaaaaaaggg ggggcgccga aaaaaggtct cgaaccggaa 3360

<210> 23
<211> 1660
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 4630911CB1

<400> 23
gtagatgaac aggaagcaac tggaggtaat acctatgatt tgggtaatat ctctagataa 60
gagtaaaggg acttttcaca taggcagtca cttcacctct acgagtctca ttttttccaa 120
ctgcacaaat acagattttc gatactttat ttatgcagtg acatacactg tcattcttgt 180
gccaggtctc atagggaata tattagccct gtgggtattc tatggttata tgaaagaaac 240
aaaacgagct gtgatattta tgataaactt agccattgct gacttactac aagttctttc 300
cttgccactg aggatcttct actacttgaa tcatgactgg ccatttgggc ctggtctctg 360
catgttctgt ttctacctga agtatgtcaa catgtatgca agcatctact tcttggtctg 420
catcagtgtg cgacgatttt ggtttctcat gtacccctttt cgcttccatg actgcaaaca 480
gaaatatgac ctgtacatca gcattgctgg ctggctgatc atctgccttg cctgtgtact 540
ctttccactc ctcagaacca gtgatgatac ccctggcaat aggaccaaat gctttgtgga 600
tcttcctacc aggaatgtca acctggccca gtccgttgtt atgatgacca ttggcgagtt 660
gattgggttt gtaactccgc ttctgattgt cctatattgt acctggaaga cggttttatc 720
actgcaagat aaatatccca tggcccaaga tcttggagag aaacagaaag ccttgaagat 780
gattctaacc tgtgcagggg tattcctaat ttgctttgca ccttatcatt tcagttttcc 840
tttagatttc ctggtgaagt ccaatgaaat taaaagctgc ctagccagaa gggtgattct 900
aatatttcat tctgtggcat tgtgtcttgc tagtctgaat tcatgtcttg acccagtcat 960
atactacttt tccactaatg agttccgaag acggctttca agacaagatt tgcatgacag 1020
catccaactc catgcaaaat cctttgtgag taaccataca gcttccacca tgacacctga 1080
attatgctaa aacaaaaaac caaactgaat gtgacctgaa atgcaagtac atcagaacat 1140
atctgcaata cccaagccac agggaagaac ttgcaaaaca acacagcttt tcagttctgc 1200
tctatcttac tgctatgggg aattcacttc ttcaaagcag gacctatttg gagcattacg 1260
atccacgatt attgatgttg acatgtccat gtagtaattt ttcttcaagt ctgtaaatct 1320
taaaatatca aatttctgtg acatcctata aacatatgca ctcaactgta gtcagtactt 1380
ttacctgtga acctcaggca caaaaagatt attagcttgg agtcaccata aacatttagt 1440
tttgttgcaa cagatactga gtctttatgt tcagaggaaa tgtaagtgtc tttttatatt 1500
agtaatcaca gtttacatgc cattttcata tgtttggtta tattttagtg ggatagatga 1560
tatattaccc tgtgtaaaga aaatgtaaac ataagatcat ttttatctct caagtgtgat 1620
tactcttcag agtttgaaga ttaaaatagc tattttcttc 1660

<210> 24
<211> 2603
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472432CB1

<400> 24
ggaccagcag aaggaagaag tatggagtta aagactgcag cgtgaactga ggagtcccgg 60
acaggccgct tgctgcagag gatccagtcc agatcccagg agagcccctc tgcccttcg 120
gacctcgtct cccatctaca aaacgtgaag attggcccag ttagcgtgtc tctacaaaaa 180
ggtgcatata ccactgcccc gctgcaggct gatctgagaa agcctctggc ccaccgccat 240
ggccttcctg atgcacctgc tggtctgcgt cttcggaatg ggctcctggg tgaccatcaa 300
tgggctctgg gtagagctgc ccctgctggt gatggagctg cccgagggct ggtacctgcc 360
ctcctacctc acggtggtca tccagctggc caacatcggg cccctcctgg tcaccctgct 420

ccatcacttc cggcccagct gcctttccga agtgcccatg atcttcaccc tgctgggcgt 480
gggaaccgtc acctgcatca tctttgcctt cctctggaat atgacctcct gggtgctgga 540
cggccaccac agcatcgcct tcttggtcct caccttcttc ctggccctgg tggactgcac 600
ctcttcagtg accttcctgc cgttcatgag ccggctgccc acctactacc tcaccacctt 660
ctttgtgggt gaaggactca gcggcctctt gcccgccctg gtggctcttg cccagggctc 720
cggtctcact acctgcgtca atgtcactga gatatcagac agcgtaccaa gccctgtacc 780
cacgagggag actgacatcg cacagggagt tcccagagct ttggtgtccg ccctccccgg 840
aatggaagca cccttgtccc acctggagag ccgctacctt cccgcccact tctcaccccc 900
ggtcttcttc ctcctcctat ccatcatgat ggcctgctgc ctcgtggcgt tctttgtcct 960
ccagcgtcaa cccaggtgct gggaggcttc cgtggaagac ctcctcaatg accaggtcac 1020
cctccactcc atccggccgc gggaagagaa tgacttgggc cctgcaggca cggtggacag 1080
cagccagggc caggggtatc tagaggagaa agcagccccc tgctgcccgg cgcacctggc 1140
cttcatctat accctggtgg ccttcgtcaa cgcgctcacc aacggcatgc tgccctctgt 1200
gcagacctac tcctgcctgt cctatgggcc agttgcctac cacctggctg ccaccctcag 1260
cattgtggcc aaccctcttg cctcgttggt ctccatgttc ctgcctaaca ggtctctgct 1320
gttcctgggg gtcctctccg tgcttgggac ctgctttggg ggctacaaca tggccatggc 1380
ggtgatgagc ccctgccccc tcttgcaggg ccactggggt ggggaagtcc tcattgtggc 1440
ctcgtgggtg cttttcagcg gctgcctcag ttacgtcaag gtgatgctgg gcgtggtcct 1500
gcgcgacctc agccgcagcg ccctcttgtg gtgcggggcg gcggtgcagc tgggctcgct 1560
gctcggagcg ctgctcatgt tccctctggt caacgtgctg cggctcttct cgtccgcgga 1620
cttctgcaat ctgcactgtc cagcctaggc aggccgccga ccccgccccc atcgctcacg 1680
gacggaactg gggtccagag aggccaggtc acagagcaag gggcaggaac agagagacag 1740
agcctgagta attgaatcat gaacgcaagt gcccactggg gactgtgggg aagatggcac 1800
ctggaaatgc aaggtgcggc tctatcccca actctgtgtc acactacctg tgacgaccag 1860
ctcagatctc ctttgctttg actctcaaga gaggactgat ttgcagcatc tagctggagg 1920
caggcccaag ggtgttagaa gggaaacagc tgggacagcc ggctgtccct tcaggctgtg 1980
tgaccttggg aaagtcattt ggcttctctg tgcctgtttc ttcatgcatg cagtggggat 2040
tccagtaagt accaactacc tcacaggcat ggcacggagg caaaaggaaa aagcagcccg 2100
catcaagcaa gccctcctgg gccacctgct gatctgacag tccatcgtag taacaagagt 2160
ggcagtctgc acaacctaga agtggccaga agggttgaga cacgcccctg ccctctctcc 2220
tttgcccctc agtctcacag aggggcttct acaagacaag cagataacga tagaatcttg 2280
ggcatcttgg ctttcggatt ctcagtgtgg agggacgtag taccccacac acccccttcct 2340
gtcatccttc ctggcccata aagcccacta gttggagagt aagtaccctc ctggaagcag 2400
ggagagatga tttgctggtg gggctgggga aggcccatcc ctgagcctct gaaagtgaac 2460
tccccgacca ggttggggac cagacatgca gagcccctgg aagtattctc tcaaatggag 2520
gcaacagagg tgattgttat tttgttttag tttctgtttt tcatttttt aaataaaggc 2580
attccctgct tttaaaaaaa aaa 2603

<210> 25
<211> 1119
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474977CB1

<400> 25
atggaggccg ctagcctttc agtggccacc gccggcgttg cccttgccct gggacccgag 60
accagcagcg ggaccccaag cccgagaggg atactcggtt cgaccccgag cggcgccgtc 120
ctgccgggcc gagggccgcc cttctctgtc ttcacggtcc tggtggtgac gctgctagtg 180
ctgctgatcg ccgccacttt cctgtggaac ctgctggttc cggtcaccat cccgcgggtc 240
cgtgccttcc accgcgtgcc gcataacttg gtggcctcga cggccgtctc ggacgaacta 300
gtggcagcgc tggcgatgcc accgagcctg gcgagtgagc tgtcgaccgg gcgacgtcgg 360
ctgctgggcc ggagcctgtg ccacgtgtgg atctccttcc acgtgctgtg ctgccccgcc 420
ggcctcggga acgtggcggc catcgccctg ggccgcgacg gggccatcac acggcacctg 480
cagcacacgc tgcgcacccg cagccgcgcc tcgttgctca tgatcgcgct cacccgggtg 540
ccgtcggcgc tcatcgccct cgcgccgctg ctctttggcc ggggcgaggt gtgcgacgct 600
cggctccagc gctgccaggt gagccgggaa ccctcctatg ccgccttctc cacccgcggc 660
gccttccacc tgccgcttgg cgtggtgccg tttgtctacc ggaagatcta cgaggcggcc 720
aagtttcgtt tcggccgccg ccggagagct gtgctgccgt tgccggccac catgcaggtg 780
aaggtaaagg aagcacctga tgaggctgaa gtggtgttca cggcacattg caaagcaacg 840
gtgtccttcc aggtgagcgg ggactcctgg cgggagcaga aggagaggcg agcagccatg 900

atggtgggaa ttctgattgg cgtgtttgtg ctgtgctgga tccccttctt cctgacggaa 960
ctcatcagcc cactctgtgc ctgcagcctg ccccccatct ggaaaagcat atttctgtgg 1020
cttggctact ccaattcttt cttcaacccc ctgatttaca cagcttttaa caagaactac 1080
aacaatgcct tcaagagcct ctttactaag cagagatga 1119

<210> 26
<211> 1018
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474848CB1

<400> 26
gggcaccagt ggaggttttc tgagcatgga tccaaccacc ccggcctggg gaacagaaag 60
tacaacagtg aatggaaatg accaagccct tcttctgctt tgtggcaagg agaccctgat 120
cccggtcttc ctgatccttt tcattgccct ggtcgggctg gtaggaaacg ggtttgtgct 180
ctggctcctg ggcttccgca tgcgcaggaa cgccttctct gtctacgtcc tcagcctggc 240
cggggccgac ttcctcttcc tctgcttcca gattataaat tgcctggtgt acctcagtaa 300
cttcttctgt tccatctcca tcaatttccc tagcttcttc accactgtga tgacctgtgc 360
ctaccttgca ggcctgagca tgctgagcac cgtcagcacc gagcgctgcc tgtccgtcct 420
gtggcccatc tggtatcgct gccgccgccc cagacacctg tcagcggtcg tgtgtgtcct 480
gctctgggcc ctgtccctac tgctgagcat cttggaaggg aagttctgtg gcttcttatt 540
tagtgatggt gactctggtt ggtgtcagac atttgatttc atcactgcag cgtggctgat 600
ttttttattc atggttctct gtgggtccag tctggccctg ctggtcagga tcctctgtgg 660
ctccaggggt ctgccactga ccaggctgta cctgaccatc ctgctcacag tgctggtgtt 720
cctcctctgc ggcctgccct ttggcattca gtggttccta atattatgga tctggaagga 780
ttctgatgtc ttattttgtc atattcatcc agtttcagtt gtcctgtcat ctcttaacag 840
cagtgccaac cccatcattt acttcttcgt gggctctttt aggaagcagt ggcggctgca 900
gcagccgatc ctcaagctgg ctctccagag ggctctgcag gacattgctg aggtggatca 960
cagtgaagga tgcttccgtc agggcacccc ggagatgtcg agaagcagtc tggtgtag 1018

<210> 27
<211> 2177
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7655614CB1

<400> 27
atggaggagc cgcagccgcc ccgcccacca gcgagcatgg ccttactggg cagccagcac 60
tccggcgccc cctccgcggc cggcccacct ggcgggactt cctccgcggc cacggcggcc 120
gtgctctcct tcagcaccgt ggcgaccgcg gcgctgggga acctgagcga cgcaagcgga 180
ggcggcacag ctgccgctcc cggtggcggc ggccttggcg ggtccggggc agcgcgggag 240
gcgggggcgg cggtgaggcg gccgctaggc ccggaggcgg cgccgctgct gtcgcacgga 300
gctgcagtgg cggcccaggc gctcgtcctc ctgctcatct tcctgctgtc tagccttggc 360
aactgcgcgg tgatgggggt gattgtgaag caccggcagc tccgcaccgt caccaacgcc 420
ttcatcctgt cgctgtccct atcggatctg ctcacggcgc tgctctgcct gcccgccgcc 480
ttcctggacc tcttcactcc gcccgggggt tcggcgcctg ccgccgccgc ggggccctgg 540
cgcggcttct gcgccgccag ccgcttcttc agctcgtgct tcggcatcgt gtccacgctc 600
agcgtggcgc tcatctcgtt ggaccgttac tgcgctatcg tgcggccgcc gcgggagaag 660
atcggccgcc gccgcgcgct gcagctgctg gcgggcgcct ggctgacggc cctgggcttc 720
tccttgccct gggagctgct cggggcgccc cgggaactcg cggcggcgca gagcttccac 780
ggctgcctct accggacctc cccggacccc gcgcagctgg gcgcggcctt cagcgtgggg 840
ctggtggtgg cctgctacct gctgcccttc ctgctcatgt gcttctgcca ctaccacatc 900
tgcaagacgg tgcgcctgtc ggacgtgcgc gtgcggccgg tgaacaccta cgcgcgcgtg 960
ctgcgcttct tcagcgaggt gcgcacggcc accaccgtcc tcatcatgat cgtcttcgtc 1020
atctgctgct gggggcccta ctgcttcctg gtgctgctgg ccgccgcccg gcaggcccag 1080
accatgcagg ccccctcgct cctcagcgtg gtggccgtct ggctgacctg ggccaatggg 1140
gccatcaacc ctgtcatcta cgccatccgc aatcccaaca tttcgatgct cctagggcgc 1200

aaccgcgagg agggctaccg gactaggaat gtggacgctt tcctgcccag ccagggcccg 1260
ggtctgcaag ccagaagccg cagtcgcctt cgaaaccgct atgccaaccg gctgggggcc 1320
tgcaacagga tgtcctcttc caacccggcc agcggagtgg caggggacgt ggccatgtgg 1380
gcccgcaaaa atccagttgt acttttctgc cgagagggac caccagagcc ggtgacggca 1440
gtgaccaaac agcctaaatc cgaagctggg gataccagcc tctaagacgg ttggaatggc 1500
cagcttatga aggcaaattt ccactcgcat tatttaatga tggaagattc tgggggagag 1560
ttgtggattt cataaagcca aacatttaaa gctagagacg ggggaggctt accactttcc 1620
ccaaacaaca taaaagacaa tgtcccttct tcaaaagtgc caaaaggaat gtaaaatgca 1680
aaaattaaaa caatcttaaa ccacataacc aagcattgtg aactgtaagt gccaaaaatg 1740
acaaaaataa cattcactat aactgaaaag ctcatattat aggaccacac tgtgaaacaa 1800
acaaaacatt gaatgcaacc agtattgttc aactacacag aatttcagga atgaatggag 1860
accttcagag ctgcttgaaa gcccctctaa atcgctacca tccaacaaaa ctttagcttc 1920
tagagcttgc acctctgaca tgctttgggt gcttagattg caagtggaaa agtcttatcc 1980
ttacacacat tggtgcacct cctcacccca ccccctaata acctttgtgg aaaattttta 2040
attcataacc catttaaaat cattttagga ttttgaaaag ctggttatta ttagataaaa 2100
ttcaaccatc tgaaggacaa atagaagtat gaacataact ttccagcaca ctgcgccgta 2160
ctagtgtcca ggctcgt 2177

<210> 28
<211> 1632
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 6792419CB1

<400> 28
ttgatgggaa gggatgaatg aataaaagta cttgtctgat ggcagcagag accccgagca 60
aacggtggag gctacactgt ctggcattct cgcagcgttt cgtcagagcc ggacccgcct 120
gcagctcaag ggaggcgtgc tcctctccca gagcaggctg gaacccagct gggttccgcc 180
tcccgggaag gtggtctcca ttcgtcgctc tgcatctggt ttgtcagatc cgagaggctc 240
tgaaactgcg gagcggccac cggacgcctt ctggagcagg tagcagcatg cagccgcctc 300
caagtctgtg cggacgcgcc ctggttgcgc tggttcttgc ctgcggcctg tcgcggatct 360
ggggagagga gagaggcttc ccgcctgaca gggccactcc gcttttgcaa accgcagaga 420
taatgacgcc acccactaag accttatggc ccaagggttc caacgccagt ctggcgcggt 480
cgttggcacc tgcggaggtg cctaaaggag acaggacggc aggatctccg ccacgcacca 540
tctcccctcc cccgtgccaa ggacccatcg agatcaagga gactttcaaa tacatcaaca 600
cggttgtgtc ctgccttgtg ttcgtgctgg ggatcatcgg gaactccaca cttctgagaa 660
ttatctacaa gaacaagtgc atgcgaaacg gtcccaatat cttgatcgcc agcttggctc 720
tgggagacct gctgcacatc gtcattgaca tccctatcaa tgtctacaag ctgctggcag 780
aggactggcc atttggagct gagatgtgta agctggtgcc tttcatacag aaagcctccg 840
tgggaatcac tgtgctgagt ctatgtgctc tgagtattga cagatatcga gctgttgctt 900
cttggagtag aattaaagga attggggttc caaaatggac agcagtagaa attgttttga 960
tttgggtggt ctctgtggtt ctggctgtcc ctgaagccat aggttttgat ataattacga 1020
tggactacaa aggaagttat ctgcgaatct gcttgcttca tcccgttcag aagacagctt 1080
tcatgcagtt ttacaagaca gcaaaagatt ggtggctgtt cagtttctat ttctgcttgc 1140
cattggccat cactgcattt ttttatacac taatgacctg tgaaatgttg agaaagaaaa 1200
gtggcatgca gattgcttta aatgatcacc taaagcagag acgggaagtg gccaaaaccg 1260
tcttttgcct ggtccttgtc tttgccctct gctggcttcc ccttcacctc agcaggattc 1320
tgaagctcac tctttataat cagaatgatc ccaatagatg tgaacttttg agctttctgt 1380
tggtattgga ctatattggt atcaacatgg cttcactgaa ttcctgcatt aacccaattg 1440
ctctgtattt ggtgagcaaa agattcaaaa actgctttaa gtcatgctta tgctgctggt 1500
gccagtcatt tgaagaaaaa cagtccttgg aggaaaagca gtcgtgctta aagttcaaag 1560
ctaatgatca cggatatgac aacttccgtt ccagtaataa atacagctca tcttgaaaga 1620
agaaaaaaaa aa 1632

<210> 29
<211> 1458
<212> DNA
<213> Homo sapiens

<220>

<221> misc_feature
<223> Incyte ID No: 7474790CB1

<400> 29
atgcccatca gcctggccca cggcatcatc cgctcaaccg tgctggttat cttcctcgcc 60
gcctctttcg tcggcaacat agtgctggcg ctagtgttgc agcgcaagcc gcagctgctg 120
caggtgacca accgttttat ctttaacctc ctcgtcaccg acctgctgca gatttcgctc 180
gtggcccgct gggtggtggc cacctctgtg cctctcttct ggcccctcaa cagccacttc 240
tgcacggccc tggttagcct cacccacctg ttcgccttcg ccagcgtcaa caccattgtc 300
gtggtgtcag tggatcgcta cttgtccatc atccaccctc tctcctaccc gtccaagatg 360
acccagcgcc gcggttacct gctcctctat ggcacctgga ttgtggccat cctgcagagc 420
actcctccac tctacggctg gggccaggct gcctttgatg agcgcaatgc tctctgctcc 480
atgatctggg gggccagccc cagctacact attctcagcg tggtgtcctt catcgtcatt 540
ccactgattg tcatgattgc ctgctactcc gtggtgttct gtgcagcccg gaggcagcat 600
gctctgctgt acaatgtcaa gagacacagc ttggaagtgc gagtcaagga ctgtgtggag 660
aatgaggatg aagagggagc agagaagaag gaggagttcc aggatgagag tgagtttcgc 720
cgccagcatg aaggtgaggt caaggccaag gagggcagaa tggaagccaa ggacggcagc 780
ctgaaggcca aggaaggaag cacggggacc agtgagagta gtgtagaggc caggggcagc 840
gaggaggtca gagagagcag cacggtggcc agcgacggca gcatggaggg taaggaaggc 900
agcaccaaag ttgaggagaa cagcatgaag gcagacaagg gtcgcacaga ggtcaaccag 960
tgcagcattg acttgggtga agatgacatg gagtttggtg aagacgacat caatttcagt 1020
gaggatgacg tcgaggcagt gaacatcccg gagagcctcc cacccagtcg tcgtaacagc 1080
aacagcaacc ctcctctgcc caggtgctac cagtgcaaag ctgctaaagt gatcttcatc 1140
atcattttct cctatgtgct atccctgggg ccctactgct ttttagcagt cctggccgtg 1200
tgggtggatg tcgaaaccca ggtaccccag tgggtgatca ccataatcat ctggcttttc 1260
ttcctgcagt gctgcatcca cccctatgtc tatggctaca tgcacaagac cattaagaag 1320
gaaatccagg acatgctgaa gaagttcttc tgcaaggaaa agcccccgaa agaagatagc 1380
cacccagacc tgcccggaac agagggtggg actgaaggca agattgtccc ttcctacgat 1440
tctgctactt ttccttga 1458

<210> 30
<211> 1015
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474816CB1

<400> 30
tgatatatat agtgtatata tacatacatg cacacataca ctatatatat caaggattta 60
tatgatagga ttaattaaga aaaaaattag tggaataaaa ataatgttta tgataatttt 120
ggccatagaa tatataatac agatgatgtg aagtacaaaa tgtttttat acttcatatt 180
ttgatgtaca aagtatgttt gtctttgtaa ttcagatgat tactttgcac ttgtgttccc 240
atgaaaaatg cctttcattt ctaagctggt attggcatct cagccaacac ttttctcctt 300
cttttctgcg tcttctcctt ttctgctttt tctggatctc aggccagagc gcacttacct 360
accagtctgt catgtggccc tcatccacat ggtggtcctt ctcaccatgg tgttcttgtc 420
tccacagctc tttgaatcac tgaatttta gaatgacttc aaatatgagg catctttcta 480
cctgaggagg gtgatcaggg acctctccat ttgtaccacc tgcctcctgg gcatgctgca 540
ggtcgtcaac atcagcccca gcatttcctg gttggtgagg tttaaatgga aatccacaat 600
ttttaccttc catttgttct catggtctct cagttttcct gttagtagta gcctgatctt 660
ttacactgtg gcttcttcca atgtgaccca gatcaatttg catgtcagta aatactgttc 720
acttttccca ataaactcca taatcagagg actgtttttc actctgtcat tattcagaga 780
tgtttttctt aaacaaataa tgctgttctc aagtgtctac atgatgactc tcattcagga 840
actacaggag atcctggtac cttcacagcc ccagcctcta cctaaggatc tttgcagagg 900
caagagccat cagcacatcc tgctgccggt gagtttctcg gtgggcatgt acaagatgga 960
cttcatcatc tcaacctcct caacgttgcc atgggcatat gaccgtggtg tctag 1015

<210> 31
<211> 2781
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7476172CB1

<400> 31
atggcattct taattatact aattacctgc tttgtgatta ttcttgctac ttcacagcct 60
tgccagaccc ctgatgactt tgtggctgcc acttctccgg gacatatcat aattggaggt 120
ttgtttgcta ttcatgaaaa aatgttgtcc tcagaagact ctcccagacg accacaaatc 180
caggagtgtg ttggctttga aatatcagtt tttcttcaaa ctcttgccat gatacacagc 240
attgagatga tcaacaattc aacactctta cctggagtca aactggggta tgaaatctat 300
gacacttgta cagaagtcac agtggcaatg gcagccactc tgaggtttct ttctaaattc 360
aactgctcca gagaaactgt ggagtttaag tgtgactatt ccagctacat gccaagagtt 420
aaggctgtca taggttctgg gtactcagaa ataactatgg ctgtctccag gatgttgaat 480
ttacagctca tgccacaggt gggttatgaa tcaactgcag aaatcctgag tgacaaaatt 540
cgctttcctt cattttacg gactgtgccc agtgacttcc atcaaattaa agcaatggct 600
cacctgattc agaaatctgg ttggaactgg attggcatca taaccacaga tgatgactat 660
ggacgattgg ctcttaacac ttttataatt caggctgaag caaataacgt gtgcatagcc 720
ttcaaagagg ttcttccagc ctttctttca gataatacca ttgaagtcag aatcaatcgg 780
acactgaaga aaatcatttt agaagcccag gttaatgtca ttgtggtatt tctgaggcaa 840
ttccatgttt ttgatctctt caataaagcc attgaaatga atataaataa gatgtggatt 900
gctagtgata attggtcaac tgccaccaag attaccacca ttcctaatgt taaaaagatt 960
ggcaaagttg tagggtttgc ctttagaaga gggaatatat cctctttcca ttcctttctt 1020
caaaatctgc acttgcttcc cagtgacagt cacaaactct tacatgaata tgccatgcat 1080
ttatctgcct gcgcatatgt caaggacact gatttgagtc aatgcatatt caatcattct 1140
caaaggactt tggcctacaa ggctaacaag gctatagaaa ggaacttcgt catgagaaat 1200
gacttcctct gggactatgc tgagccagga ctcattcata gtattcagct tgcagtgttt 1260
gcccttggtt atgccattcg ggatctgtgt caagctcgtg actgtcagaa ccccaacgcc 1320
tttcaaccat gggagttact tggtgtgcta aaaaatgtga cattcactga tggatggaat 1380
tcatttcatt ttgatgctca cggggattta aatactggat atgatgttgt gctctggaag 1440
gagatcaatg gacacatgac tgtcactaag atggcagaat atgacctaca gaatgatgtc 1500
ttcatcatcc cagatcagga aacaaaaaat gagttcagga atcttaagca aattcaatct 1560
aaatgctcca aggaatgcag tcctgggcaa atgaagaaaa ctacaagaag tcaacacatc 1620
tgttgctatg aatgtcagaa ctgtcctgaa aatcattaca ctaatcagac agatatgcct 1680
cactgccttt tatgcaacaa caaaactcac tgggcccctg ttaggagcac tatgtgcttt 1740
gaaaaggaag tggaatatct caactggaat gactccttgg ccatcctact cctgattctc 1800
tccctactgg gaatcatatt tgttctggtt gttggcataa tatttacaag aaacctgaac 1860
acacctgttg tgaaatcatc cgggggatta agagtctgct atgtgatcct tctctgtcat 1920
ttcctcaatt ttgccagcac gagcttttc attggagaac cacaagactt cacatgtaaa 1980
accaggcaga caatgtttgg agtgagcttt actctttgca tctcctgcat tttgacgaag 2040
tctctgaaaa ttttgctagc cttcagcttt gatcccaaat tacagaaatt tctgaagtgc 2100
ctctatagac cgatccttat tatcttcact tgcacgggca tccaggttgt catttgcaca 2160
ctctggctaa tctttgcagc acctactgta gaggtgaatg tctccttgcc cagagtcatc 2220
atcctggagt gtgaggaggg atccatactt gcatttggca ccatgctggg ctacattgcc 2280
atcctggcct tcatttgctt catatttgct ttcaaaggca aatatgagaa ttacaatgaa 2340
gccaaattca ttacatttgg catgctcatt tacttcatag cttggatcac attcatccct 2400
atctatgcta ccacatttgg caaatatgta ccagctgtgg agattattgt catattaata 2460
tctaactatg gaatcctgta ttgcacattc atccccaaat gctatgttat tatttgtaag 2520
caagagatta acacaaagtc tgcctttctc aagatgatct acagttattc ttcccatagt 2580
gtgagcagca ttgccctgag tcctgcttca ctggactcca tgagcggcaa tgtcacaatg 2640
accaatccca gctctagtgg caagtctgca acctggcaga aaagcaaaga tcttcaggca 2700
caagcatttg cacacatatg cagggaaaat gccacaagtg tatctaaaac tttgcctcga 2760
aaaagaatgt caagtatatg a 2781

<210> 32
<211> 1267
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472141CB1

<400> 32

ccccctccct tccccccgga ggggggggaaa accatgtaaa ctctcacagc tctaaaaaat 60
ccctttatgt cccttggtct gcatctccta tgaaaagacg ttaataatag aaacgatccc 120
caatttacaa tgcttgaatc gcactacaca ccacaaattc acgcttaata tttttatggg 180
ctgataggca aatatctaaa acattcacaa gaacttcgcc cgcttttaga aactactctc 240
atgaactatc tttcagctgg catcaactta ttcgcctact aagacttatg gacaagactg 300
ttagtattcc acaaactatc ctatcttttc tttttaaatg ttattgaatc acacattaat 360
cactgaattt ctcctcttgg gggtgacaga catacaagaa ttaaacccta ttctttttgt 420
catggtcctt gccatgtact ttataaatgt gtttgggaat ggagccatca tgatgattgt 480
catcttagat ccaagactct actcacctat gtatttcttc ctgggaaacc tagcatgcct 540
agatatctgc ttctccactg taacagtgcc aaaaatgctg gagaacttct tctctacaag 600
caaagcaatt tccttcttgg gatgcataac tcaacttcat ttcttccact tcttgggaag 660
cacagaagcc ctgctgctga cagtgatggc atttgaccgc tttgtggcta tctgcagacc 720
actccactac cctgtcatca tgaatcgcca gctctgtatt cacatgactg ttactatctg 780
gaccattggc tttttccatg ccctgcttca ctctgtaatg acatctcgtt tgagcttctg 840
tggttccaat catatccatc atttcttctg tgatgttaag ccattactgg atctggcctg 900
tggaaacact gagctcaacc tttggctgct caatacagtc acaggcacca ttgccctcac 960
ttccttttat ctgatatttc tctcttattt ctacatcatc accaatcttc tcctcaagac 1020
ccgttcttgc agcatgctcc acaaagctct gtctacctgt gcctcccact tcatggttgt 1080
tgttctgttc tatgctcctg ttctcttcac ctacatccgt cctgcctcag gcagctctct 1140
ggatcaggat acaatcatcg ccatcatgta cagtgtggtc acccctgctc tcaatccact 1200
catgtacacc ttgagaaaca aggaagtgag gagtgcattg aatagaaagg tgagaagctc 1260
cctttga 1267

<210> 33
<211> 1559
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7472137CB1

<400> 33
atagtttgcc tgacatttta gcagatactt cataaacttt actataatgc taggatattg 60
tgttaccgat gtgttataat aagtatgatt tccattggca gatgatgaaa ctaagtctat 120
gaaagacgtc atgtaaatgt tttaacaagt atagctaata aatggagagg ccaggattca 180
tattaagttt tctggtttct aacctaatta tttttctgtt acattgcaga gggcaatgaa 240
cagtggaagt ttcttatgta aagacatcac aagagttcaa atagtaaata tgctcaaaaa 300
gaataaatcc atggtacata ggcttctaac ttaagctaaa gtgttttaaa tatgcctcta 360
aacttctcat cctgtagaag acaagaatct gcctttacaa agcatccctt ccatgagtcg 420
aatagactga ctctaaaata ggcatttcct tattatctga ttttttttta catggatctc 480
tctcttgcct ttcataagaa ggcaggttgt tccttgttaa aaacatagcc aaagcactca 540
tcagcaaaaa gcttgagaac ttgacattgg tgtttagact tggtgtcttg ggtacctttt 600
caaggttgga tgttttcaca gccatgagga atttctcggt ggtgtccgaa ttcatcctgc 660
tgggcatccc tcacacggag ggtctggaga ctattctgtt ggtcctgttt ttgtccttct 720
acatcttcac ccttatgggg aacctgctca tcttgctggc tattgtctcc tctgctcggc 780
ttcacacgcc catgtacttc ttcctgtgca agctgtctgt ttttgaccta tttttccctt 840
ctgtgagttc ccctaagatg ctgtgctatc tttcagggaa cagccgagcc atctcctatg 900
caggctgtgc atcccagctc ttcttctacc atttcctggg ctgcactgag tgtttcctgt 960
acacggtgat ggcctacgac cgctttgttg ccatttgtca ccctctacgc tacaccataa 1020
tcatgagcca cagagcatgt atcatcctag ccatggggac ctcattcttt ggctgcattc 1080
aggccacctt tctgaccact ctcaccttcc aattgcctta ctgtgtcccc aatgaggtgg 1140
actattattt ctgtgatatc ccagtcatgc tgaagctggc ttgtgcagat acctcagccc 1200
tggagatggt ggggttcatc agtgtgggcc tcatgccccc cagctgtttc cttctcatcc 1260
tcacctccta cagtggcatc gtcttctcca tcttgtagat ctgctctgcc gagggccgac 1320
gccgtgcctt ctccacctgc agcgcccacc tcaccgccat cctgcttttt tacatgccag 1380
tggtcctcat ttacctgagg cctacccaca gcctgtggtt ggatgcaact gttcaaattc 1440
tgaataacct ggtcaccccc atgctgaacc ccttaatcta cagtctcagg aataaggagg 1500
tgaaattatc actaaggaag gtcttatatc agctgggctt ccttcctgag cagttgtag 1559

<210> 34
<211> 981
<212> DNA

<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7477934CB1

<400> 34
atgggccatc agaatcacac tttcagcagt gatttcatac ttttgggatt gttctcttct 60
aacaagtgtg gtcttcttct tagacaattt gtcattttca ttatgagtgt aacagaaaat 120
acgctcatga tcctcctcat tcgcagtgac tcccgactcc acactccaat gtattttctg 180
ctcagccatc tctccttaat ggatatcttg catgtttcca acatcgttcc caaaatggtc 240
actaactttc tgtcaggcag cagaactatt tcatttgcag gttgtgggtt ccaggtattt 300
ctgtccctca ccctcctggg tggtgagtgc cttctcctgg ctgcaatgtc ctgtgatcgc 360
tatgtggcta tctgtcaccc gctgcgctat ccgattctta tgaaggagta tgccagcgct 420
ctcatggctg gaggctcctg gctcattggg gttttcaact ccacagtcca cacagcttat 480
gcactgcagt ttcccttctg tggctctagg gcaattgatc acttcttctg tgaagtccct 540
gccatgttga agttgtcctg tgcagacaca acacgctatg aacgaggggt ttgtgtaagt 600
gctgtgatct tcctgctgat ccctttctcc ttgatctctg cttcttatgg ccaaattatt 660
cttactgtcc tccagatgaa atcatcagag gcaaggaaaa agtcatttc cacttgttcc 720
ttccacatga ttgtggtcac gatgtactat gggccattta tttttacata tatgagacct 780
aaatcatacc acactccagg ccaggataag ttcctggcaa tattctatac gatcctcaca 840
cccacactca acccttttcat ctacagcttt aggaataaag atgttctggc ggtgatgaaa 900
aatatgctca aaagtaactt tctgcacaaa aaaatgaata ggaaaattcc tgaatgtgtg 960
ttctgtctat ttctatgtta a 981

<210> 35
<211> 2177
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7655614CB1.comp

<400> 35
acgagcctgg acactagtac ggcgcagtgt gctggaaagt tatgttcata cttctatttg 60
tccttcagat ggttgaattt tatctaataa taaccagctt ttcaaaatcc taaaatgatt 120
ttaaatgggt tatgaattaa aaattttcca caaaggttat taggggtgg ggtgaggagg 180
tgcaccaatg tgtgtaagga taagactttt ccacttgcaa tctaagcacc caaagcatgt 240
cagaggtgca agctctagaa gctaaagttt tgttggatgg tagcgattta gaggggcttt 300
caagcagctc tgaaggtctc cattcattcc tgaaattctg tgtagttgaa caatactggt 360
tgcattcaat gttttgtttg tttcacagtg tggtcctata atatgagctt ttcagttata 420
gtgaatgtta tttttgtcat ttttggcact tacagttcac aatgcttggt tatgtggttt 480
aagattgttt taatttttgc attttacatt ccttttggca cttttgaaga agggacattg 540
tcttttatgt tgtttgggga aagtggtaag cctcccccgt ctctagcttt aaatgtttgg 600
ctttatgaaa tccacaactc tcccccagaa tcttccatca ttaaataatg cgagtggaaa 660
tttgccttca taagctggcc attccaaccg tcttagaggc tggtatcccc agcttcggat 720
ttaggctgtt tggtcactgc cgtcaccggc tctggtggtc cctctcggca gaaaagtaca 780
actggatttt tgcgggccca catggccacg tcccctgcca ctccgctggc cgggttggaa 840
gaggacatcc tgttgcaggc ccccagccgg ttggcatagc ggtttcgaag gcgactgcgg 900
cttctggctt gcagacccgg gccctggctg ggcaggaaag cgtccacatt cctagtccgg 960
tagccctcct cgcggttgcg ccctaggagc atcgaaatgt tgggattgcg gatggcgtag 1020
atgacagggt tgatggcccc attggcccag gtcagccaga cggccaccac gctgaggagc 1080
gaggggcct gcatggtctg ggcctgccgg gcggcggcca gcagcaccag gaagcagtag 1140
ggccccccagc agcagatgac gaagacgatc atgatgagga cggtggtggc cgtgcgcacc 1200
tcgctgaaga agcgcagcac gcgcgcgtag gtgttcaccg gccgcacgcg cacgtccgac 1260
aggcgcaccg tcttgcagat gtggtagtgg cagaagcaca tgagcaggaa gggcagcagg 1320
tagcaggcca ccaccagccc cacgctgaag gccgcgccca gctgcgcggg gtccggggag 1380
gtccggtaga ggcagccgtg gaagctctgc gccgccgcga gttcccgggg cgccccgagc 1440
agctcccagg gcaaggagaa gcccagggcc gtcagccagg cgcccgccag cagctgcagc 1500
gcgcggcggc ggccgatctt ctcccgcggc ggccgcacga tagcgcagta acggtccaac 1560
gagatgagcg ccacgctgag cgtggacacg atgccgaagc acgagctgaa gaagcggctg 1620
gcggcgcaga agccgcgcca gggccccgcg gcggcggcag gcgccgaacc cccgggcgga 1680

```
gtgaagaggt ccaggaaggc ggcgggcagg cagagcagcg ccgtgagcag atccgatagg 1740
gacagcgaca ggatgaaggc gttggtgacg gtgcggagct gccggtgctt cacaatcacc 1800
cccatcaccg cgcagttgcc aaggctagac agcaggaaga tgagcaggag gacgagcgcc 1860
tgggccgcca ctgcagctcc gtgcgacagc agcggcgccg cctccgggcc tagcggccgc 1920
ctcaccgccg cccccgcctc ccgcgctgcc ccggacccgc caaggccgcc gccaccggga 1980
gcggcagctg tgccgcctcc gcttgcgtcg ctcaggttcc ccagcgccgc ggtcgccacg 2040
gtgctgaagg agagcacggc cgccgtggcc gcggaggaag tcccgccagg tgggccggcc 2100
gcggaggggg cgccggagtg ctggctgccc agtaaggcca tgctcgctgg tgggcggggc 2160
ggctgcggct cctccat                                                2177
```